WO2006114402A1 - Substituted octahydroisoindoles as antagonists of melanin concentrating hormone receptor 1 (mch1r) - Google Patents
Substituted octahydroisoindoles as antagonists of melanin concentrating hormone receptor 1 (mch1r) Download PDFInfo
- Publication number
- WO2006114402A1 WO2006114402A1 PCT/EP2006/061782 EP2006061782W WO2006114402A1 WO 2006114402 A1 WO2006114402 A1 WO 2006114402A1 EP 2006061782 W EP2006061782 W EP 2006061782W WO 2006114402 A1 WO2006114402 A1 WO 2006114402A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dimethoxyphenyl
- isoindol
- methyloctahydro
- trifluoromethyl
- trifluoroacetate
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title claims description 20
- 101000581402 Homo sapiens Melanin-concentrating hormone receptor 1 Proteins 0.000 title description 4
- 102000044674 Melanin-concentrating hormone receptor 1 Human genes 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 104
- 238000011282 treatment Methods 0.000 claims abstract description 42
- 150000003839 salts Chemical class 0.000 claims abstract description 18
- 238000011321 prophylaxis Methods 0.000 claims abstract description 17
- 230000036528 appetite Effects 0.000 claims abstract description 15
- 235000019789 appetite Nutrition 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 230000003287 optical effect Effects 0.000 claims abstract description 7
- 150000004677 hydrates Chemical class 0.000 claims abstract description 4
- 239000000651 prodrug Chemical group 0.000 claims abstract description 4
- 229940002612 prodrug Drugs 0.000 claims abstract description 4
- 150000001204 N-oxides Chemical group 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 57
- -1 (difluoromethyl)thio, fluoro, iodo, methoxy, methyl Chemical group 0.000 claims description 52
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 37
- 208000008589 Obesity Diseases 0.000 claims description 29
- 235000020824 obesity Nutrition 0.000 claims description 29
- 102000005962 receptors Human genes 0.000 claims description 25
- 108020003175 receptors Proteins 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 21
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 18
- 206010012601 diabetes mellitus Diseases 0.000 claims description 16
- 208000019901 Anxiety disease Diseases 0.000 claims description 15
- 230000036506 anxiety Effects 0.000 claims description 15
- 150000001412 amines Chemical class 0.000 claims description 14
- 239000004202 carbamide Substances 0.000 claims description 14
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 13
- 206010046543 Urinary incontinence Diseases 0.000 claims description 13
- 201000001421 hyperglycemia Diseases 0.000 claims description 13
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 239000000556 agonist Substances 0.000 claims description 8
- 229940124757 MC-4 agonist Drugs 0.000 claims description 7
- 230000003579 anti-obesity Effects 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 4
- 239000007822 coupling agent Substances 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- WGSXKYXKAARAKD-UHFFFAOYSA-N 1-fluoro-3-isocyanato-5-(trifluoromethyl)benzene Chemical group FC1=CC(N=C=O)=CC(C(F)(F)F)=C1 WGSXKYXKAARAKD-UHFFFAOYSA-N 0.000 claims description 3
- QCWTWMJMLSKQCJ-UHFFFAOYSA-N Isonicotinic acid N-oxide Chemical compound OC(=O)C1=CC=[N+]([O-])C=C1 QCWTWMJMLSKQCJ-UHFFFAOYSA-N 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 125000004076 pyridyl group Chemical group 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 claims description 3
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims description 2
- 125000004361 3,4,5-trifluorophenyl group Chemical group [H]C1=C(F)C(F)=C(F)C([H])=C1* 0.000 claims description 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 2
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims description 2
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims description 2
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 2
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 2
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 claims description 2
- 230000010933 acylation Effects 0.000 claims description 2
- 238000005917 acylation reaction Methods 0.000 claims description 2
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical class ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 claims description 2
- 125000001246 bromo group Chemical group Br* 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 239000012948 isocyanate Substances 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 2
- AJAAIASOXWYVFZ-OSWMTFESSA-N 1-[(3as,5r,7ar)-7a-(3,4-dimethoxyphenyl)-2-methyl-3,3a,4,5,6,7-hexahydro-1h-isoindol-5-yl]-3-(2,5-difluorophenyl)urea Chemical compound C1=C(OC)C(OC)=CC=C1[C@@]1(CC[C@H](C2)NC(=O)NC=3C(=CC=C(F)C=3)F)[C@H]2CN(C)C1 AJAAIASOXWYVFZ-OSWMTFESSA-N 0.000 claims 1
- NZUWTGHVOISMHN-UHFFFAOYSA-N 1-oxidopyridin-1-ium-4-carboxamide Chemical compound NC(=O)C1=CC=[N+]([O-])C=C1 NZUWTGHVOISMHN-UHFFFAOYSA-N 0.000 claims 1
- JXHWAPDBDXPBEQ-UHFFFAOYSA-N 4-bromo-2-(trifluoromethyl)benzoic acid Chemical group OC(=O)C1=CC=C(Br)C=C1C(F)(F)F JXHWAPDBDXPBEQ-UHFFFAOYSA-N 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- AOMADVJUOQWZMD-VFJBSUHHSA-N n-[(3ar,5s,7as)-7a-(3,4-dimethoxyphenyl)-2-methyl-3,3a,4,5,6,7-hexahydro-1h-isoindol-5-yl]-3-fluoro-4-(trifluoromethyl)benzamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=C(OC)C(OC)=CC=C1[C@]1(CC[C@@H](C2)NC(=O)C=3C=C(F)C(=CC=3)C(F)(F)F)[C@@H]2CN(C)C1 AOMADVJUOQWZMD-VFJBSUHHSA-N 0.000 claims 1
- AOMADVJUOQWZMD-CNSGDJMRSA-N n-[(3as,5r,7ar)-7a-(3,4-dimethoxyphenyl)-2-methyl-3,3a,4,5,6,7-hexahydro-1h-isoindol-5-yl]-3-fluoro-4-(trifluoromethyl)benzamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=C(OC)C(OC)=CC=C1[C@@]1(CC[C@H](C2)NC(=O)C=3C=C(F)C(=CC=3)C(F)(F)F)[C@H]2CN(C)C1 AOMADVJUOQWZMD-CNSGDJMRSA-N 0.000 claims 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 1
- 102100027375 Melanin-concentrating hormone receptor 1 Human genes 0.000 abstract 1
- 108700036626 Melanin-concentrating hormone receptor 1 Proteins 0.000 abstract 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 55
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- 239000007858 starting material Substances 0.000 description 35
- 239000000203 mixture Substances 0.000 description 33
- 230000000052 comparative effect Effects 0.000 description 26
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 22
- 239000007787 solid Substances 0.000 description 22
- 239000000243 solution Substances 0.000 description 18
- 238000005481 NMR spectroscopy Methods 0.000 description 17
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 208000035475 disorder Diseases 0.000 description 15
- 239000007921 spray Substances 0.000 description 15
- 101800002739 Melanin-concentrating hormone Proteins 0.000 description 13
- ORRDHOMWDPJSNL-UHFFFAOYSA-N melanin concentrating hormone Chemical compound N1C(=O)C(C(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)C(NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(NC(=O)C(N)CC(O)=O)C(C)O)CCSC)CSSCC(C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)C)C(O)=O)NC(=O)C2CCCN2C(=O)C(CCCNC(N)=N)NC(=O)C1CC1=CC=C(O)C=C1 ORRDHOMWDPJSNL-UHFFFAOYSA-N 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 102400001132 Melanin-concentrating hormone Human genes 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 239000011324 bead Substances 0.000 description 9
- 241000282414 Homo sapiens Species 0.000 description 8
- 238000002953 preparative HPLC Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 5
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 235000013877 carbamide Nutrition 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- AFABGHUZZDYHJO-UHFFFAOYSA-N 2-Methylpentane Chemical compound CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- DAHIQPJTGIHDGO-UHFFFAOYSA-N mesembrine Natural products C1=C(OC)C(OC)=CC=C1C1(CCC(=O)C2)C2N(C)CC1 DAHIQPJTGIHDGO-UHFFFAOYSA-N 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102000016267 Leptin Human genes 0.000 description 3
- 108010092277 Leptin Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 239000002830 appetite depressant Substances 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 210000003016 hypothalamus Anatomy 0.000 description 3
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 3
- 229940039781 leptin Drugs 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- DAHIQPJTGIHDGO-IAGOWNOFSA-N mesembrine Chemical compound C1=C(OC)C(OC)=CC=C1[C@]1(CCC(=O)C2)[C@@H]2N(C)CC1 DAHIQPJTGIHDGO-IAGOWNOFSA-N 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- KNNVXVXJHXOKMV-DYVFJYSZSA-N (3as,7ar)-7a-(3,4-dimethoxyphenyl)-2-methyl-1,3,3a,4,6,7-hexahydroisoindol-5-one Chemical compound C1=C(OC)C(OC)=CC=C1[C@@]1(CCC(=O)C2)[C@H]2CN(C)C1 KNNVXVXJHXOKMV-DYVFJYSZSA-N 0.000 description 2
- AFUXOPHOMDRSSC-OSWMTFESSA-N 1-[(3as,5r,7ar)-7a-(3,4-dimethoxyphenyl)-2-methyl-3,3a,4,5,6,7-hexahydro-1h-isoindol-5-yl]-3-[4-fluoro-3-(trifluoromethyl)phenyl]urea Chemical compound C1=C(OC)C(OC)=CC=C1[C@@]1(CC[C@H](C2)NC(=O)NC=3C=C(C(F)=CC=3)C(F)(F)F)[C@H]2CN(C)C1 AFUXOPHOMDRSSC-OSWMTFESSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- XBTHHWYOEISJNF-UHFFFAOYSA-N 2-fluoro-1-isocyanato-3-(trifluoromethyl)benzene Chemical compound FC1=C(N=C=O)C=CC=C1C(F)(F)F XBTHHWYOEISJNF-UHFFFAOYSA-N 0.000 description 2
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241001601440 Mesembryanthemum tortuosum Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 206010033307 Overweight Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000004634 feeding behavior Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960004275 glycolic acid Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 150000002430 hydrocarbons Chemical group 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000012587 nuclear overhauser effect experiment Methods 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 2
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 229940002552 xenical Drugs 0.000 description 2
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- LSKOUPSEWMJCEP-UHFFFAOYSA-N 1,2,3-trifluoro-4-isocyanatobenzene Chemical compound FC1=CC=C(N=C=O)C(F)=C1F LSKOUPSEWMJCEP-UHFFFAOYSA-N 0.000 description 1
- YBWJVFMNWMLZEN-UHFFFAOYSA-N 1,2-difluoro-4-isocyanatobenzene Chemical compound FC1=CC=C(N=C=O)C=C1F YBWJVFMNWMLZEN-UHFFFAOYSA-N 0.000 description 1
- WUCCJYOIAJTFFQ-UHFFFAOYSA-N 1,3-difluoro-5-isocyanatobenzene Chemical compound FC1=CC(F)=CC(N=C=O)=C1 WUCCJYOIAJTFFQ-UHFFFAOYSA-N 0.000 description 1
- PEQMJVGRHNZPAM-UHFFFAOYSA-N 1,4-dichloro-2-isocyanatobenzene Chemical compound ClC1=CC=C(Cl)C(N=C=O)=C1 PEQMJVGRHNZPAM-UHFFFAOYSA-N 0.000 description 1
- SNHIIFOXCRYGGY-UHFFFAOYSA-N 1,4-difluoro-2-isocyanatobenzene Chemical compound FC1=CC=C(F)C(N=C=O)=C1 SNHIIFOXCRYGGY-UHFFFAOYSA-N 0.000 description 1
- AFUXOPHOMDRSSC-READRUSDSA-N 1-[(3ar,5s,7as)-7a-(3,4-dimethoxyphenyl)-2-methyl-3,3a,4,5,6,7-hexahydro-1h-isoindol-5-yl]-3-[4-fluoro-3-(trifluoromethyl)phenyl]urea Chemical compound C1=C(OC)C(OC)=CC=C1[C@]1(CC[C@@H](C2)NC(=O)NC=3C=C(C(F)=CC=3)C(F)(F)F)[C@@H]2CN(C)C1 AFUXOPHOMDRSSC-READRUSDSA-N 0.000 description 1
- AYQMNFRCBKOMIA-UHFFFAOYSA-N 1-benzazepin-2-one Chemical class O=C1C=CC=C2C=CC=CC2=N1 AYQMNFRCBKOMIA-UHFFFAOYSA-N 0.000 description 1
- HHIRBXHEYVDUAM-UHFFFAOYSA-N 1-chloro-3-isocyanatobenzene Chemical compound ClC1=CC=CC(N=C=O)=C1 HHIRBXHEYVDUAM-UHFFFAOYSA-N 0.000 description 1
- NBJZEUQTGLSUOB-UHFFFAOYSA-N 1-chloro-4-isocyanato-2-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC(N=C=O)=CC=C1Cl NBJZEUQTGLSUOB-UHFFFAOYSA-N 0.000 description 1
- RIKWVZGZRYDACA-UHFFFAOYSA-N 1-fluoro-3-isocyanatobenzene Chemical compound FC1=CC=CC(N=C=O)=C1 RIKWVZGZRYDACA-UHFFFAOYSA-N 0.000 description 1
- OPPYFFRLKJUEOS-UHFFFAOYSA-N 1-fluoro-4-isocyanato-2-(trifluoromethyl)benzene Chemical compound FC1=CC=C(N=C=O)C=C1C(F)(F)F OPPYFFRLKJUEOS-UHFFFAOYSA-N 0.000 description 1
- KVMKUTIUJGYHBA-UHFFFAOYSA-N 1-iodo-4-isocyanatobenzene Chemical compound IC1=CC=C(N=C=O)C=C1 KVMKUTIUJGYHBA-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- ODSNARDHJFFSRH-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-isoindole Chemical group C1CCCC2CNCC21 ODSNARDHJFFSRH-UHFFFAOYSA-N 0.000 description 1
- OLBJNSPBWLCTOT-UHFFFAOYSA-N 2,4-dichloro-1-isocyanatobenzene Chemical compound ClC1=CC=C(N=C=O)C(Cl)=C1 OLBJNSPBWLCTOT-UHFFFAOYSA-N 0.000 description 1
- RLRUKKDFNWXXRT-UHFFFAOYSA-N 2,5-difluorobenzoyl chloride Chemical compound FC1=CC=C(F)C(C(Cl)=O)=C1 RLRUKKDFNWXXRT-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- XVIPJBUXMFLHSI-UHFFFAOYSA-N 2-chloro-1-fluoro-4-isocyanatobenzene Chemical compound FC1=CC=C(N=C=O)C=C1Cl XVIPJBUXMFLHSI-UHFFFAOYSA-N 0.000 description 1
- OOAHPLWBUUTFMV-UHFFFAOYSA-N 2-fluoro-4-(trifluoromethyl)benzoyl chloride Chemical compound FC1=CC(C(F)(F)F)=CC=C1C(Cl)=O OOAHPLWBUUTFMV-UHFFFAOYSA-N 0.000 description 1
- SZRDJHHKIJHJHQ-UHFFFAOYSA-N 3,4,5-trifluoroaniline Chemical compound NC1=CC(F)=C(F)C(F)=C1 SZRDJHHKIJHJHQ-UHFFFAOYSA-N 0.000 description 1
- VTXNOVCTHUBABW-UHFFFAOYSA-N 3,4-dichlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C(Cl)=C1 VTXNOVCTHUBABW-UHFFFAOYSA-N 0.000 description 1
- RPQWXGVZELKOEU-UHFFFAOYSA-N 3,4-difluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1F RPQWXGVZELKOEU-UHFFFAOYSA-N 0.000 description 1
- LGDHZCLREKIGKJ-UHFFFAOYSA-N 3,4-dimethoxyaniline Chemical compound COC1=CC=C(N)C=C1OC LGDHZCLREKIGKJ-UHFFFAOYSA-N 0.000 description 1
- VIOBGCWEHLRBEP-UHFFFAOYSA-N 3,4-dimethoxybenzoyl chloride Chemical compound COC1=CC=C(C(Cl)=O)C=C1OC VIOBGCWEHLRBEP-UHFFFAOYSA-N 0.000 description 1
- KIASSQJJEIOJHJ-UHFFFAOYSA-N 3-(3,4-dimethoxyphenyl)-1-methylpyrrole-2,5-dione Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)N(C)C1=O KIASSQJJEIOJHJ-UHFFFAOYSA-N 0.000 description 1
- ZVIXUSUALFIBIJ-UHFFFAOYSA-N 3-(difluoromethyl)benzenecarbothioyl chloride Chemical compound FC(F)C1=CC=CC(C(Cl)=S)=C1 ZVIXUSUALFIBIJ-UHFFFAOYSA-N 0.000 description 1
- RUJYJCANMOTJMO-UHFFFAOYSA-N 3-(trifluoromethyl)benzoyl chloride Chemical compound FC(F)(F)C1=CC=CC(C(Cl)=O)=C1 RUJYJCANMOTJMO-UHFFFAOYSA-N 0.000 description 1
- PBOOZQFGWNZNQE-UHFFFAOYSA-N 3-bromobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC(Br)=C1 PBOOZQFGWNZNQE-UHFFFAOYSA-N 0.000 description 1
- VBYJOUAMJITBNL-UHFFFAOYSA-N 3-chloro-2-fluorobenzoyl chloride Chemical compound FC1=C(Cl)C=CC=C1C(Cl)=O VBYJOUAMJITBNL-UHFFFAOYSA-N 0.000 description 1
- WHIHIKVIWVIIER-UHFFFAOYSA-N 3-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC(Cl)=C1 WHIHIKVIWVIIER-UHFFFAOYSA-N 0.000 description 1
- RPESZQVUWMFBEO-UHFFFAOYSA-N 3-cyanobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC(C#N)=C1 RPESZQVUWMFBEO-UHFFFAOYSA-N 0.000 description 1
- DPDAEMNQJYDHRQ-UHFFFAOYSA-N 3-fluoro-4-(trifluoromethyl)benzoyl chloride Chemical compound FC1=CC(C(Cl)=O)=CC=C1C(F)(F)F DPDAEMNQJYDHRQ-UHFFFAOYSA-N 0.000 description 1
- BGAKSLBTFLVNAH-UHFFFAOYSA-N 3-fluoro-5-(trifluoromethyl)benzoyl chloride Chemical compound FC1=CC(C(Cl)=O)=CC(C(F)(F)F)=C1 BGAKSLBTFLVNAH-UHFFFAOYSA-N 0.000 description 1
- SYVNVEGIRVXRQH-UHFFFAOYSA-N 3-fluorobenzoyl chloride Chemical compound FC1=CC=CC(C(Cl)=O)=C1 SYVNVEGIRVXRQH-UHFFFAOYSA-N 0.000 description 1
- NZHPVPMRNASEQK-UHFFFAOYSA-N 3-isocyanatobenzonitrile Chemical compound O=C=NC1=CC=CC(C#N)=C1 NZHPVPMRNASEQK-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- OXZYBOLWRXENKT-UHFFFAOYSA-N 4-(trifluoromethyl)benzoyl chloride Chemical compound FC(F)(F)C1=CC=C(C(Cl)=O)C=C1 OXZYBOLWRXENKT-UHFFFAOYSA-N 0.000 description 1
- BCMFTOCCLOAGBP-UHFFFAOYSA-N 4-(trifluoromethylsulfanyl)benzoyl chloride Chemical compound FC(F)(F)SC1=CC=C(C(Cl)=O)C=C1 BCMFTOCCLOAGBP-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- UZFHKVBCBXPKKE-UHFFFAOYSA-N 4-bromo-1-isocyanato-2-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC(Br)=CC=C1N=C=O UZFHKVBCBXPKKE-UHFFFAOYSA-N 0.000 description 1
- PVXGJCNXMPLCJU-UHFFFAOYSA-N 4-bromo-3-methylbenzoyl chloride Chemical compound CC1=CC(C(Cl)=O)=CC=C1Br PVXGJCNXMPLCJU-UHFFFAOYSA-N 0.000 description 1
- DENKGPBHLYFNGK-UHFFFAOYSA-N 4-bromobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Br)C=C1 DENKGPBHLYFNGK-UHFFFAOYSA-N 0.000 description 1
- RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 description 1
- USEDMAWWQDFMFY-UHFFFAOYSA-N 4-cyanobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(C#N)C=C1 USEDMAWWQDFMFY-UHFFFAOYSA-N 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- BUDISZQHCHGLJW-UHFFFAOYSA-N 4-fluoro-3-(trifluoromethyl)benzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1C(F)(F)F BUDISZQHCHGLJW-UHFFFAOYSA-N 0.000 description 1
- CZKLEJHVLCMVQR-UHFFFAOYSA-N 4-fluorobenzoyl chloride Chemical compound FC1=CC=C(C(Cl)=O)C=C1 CZKLEJHVLCMVQR-UHFFFAOYSA-N 0.000 description 1
- NJAKCIUOTIPYED-UHFFFAOYSA-N 4-iodobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(I)C=C1 NJAKCIUOTIPYED-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 101150078806 BCAT2 gene Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229910014263 BrF3 Inorganic materials 0.000 description 1
- 102100026413 Branched-chain-amino-acid aminotransferase, mitochondrial Human genes 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- HDXBGYVRNKMYMG-PXAZEXFGSA-N CN(C([C@@H](CC(CC1)=O)[C@@]11c(cc2OC)ccc2OC)=O)C1=O Chemical compound CN(C([C@@H](CC(CC1)=O)[C@@]11c(cc2OC)ccc2OC)=O)C1=O HDXBGYVRNKMYMG-PXAZEXFGSA-N 0.000 description 1
- UZWIDCMJIZJSJM-BZQUDMEWSA-N CN(CC1C[C@@H](CC2)NC(c(cc3)ccc3SC(F)(F)F)=O)C[C@@]12c(cc1OC)ccc1OC Chemical compound CN(CC1C[C@@H](CC2)NC(c(cc3)ccc3SC(F)(F)F)=O)C[C@@]12c(cc1OC)ccc1OC UZWIDCMJIZJSJM-BZQUDMEWSA-N 0.000 description 1
- VMKBGFUOKIIGDQ-QAPCUYQASA-N CN(C[C@H]1CC2(CC3)OCCO2)C[C@@]13c(cc1OC)ccc1OC Chemical compound CN(C[C@H]1CC2(CC3)OCCO2)C[C@@]13c(cc1OC)ccc1OC VMKBGFUOKIIGDQ-QAPCUYQASA-N 0.000 description 1
- KZAPNQXZXCIUIN-OSWMTFESSA-N CN(C[C@H]1C[C@@H](CC2)NC(Nc(cc3Cl)ccc3F)=O)C[C@@]12c(cc1OC)ccc1OC Chemical compound CN(C[C@H]1C[C@@H](CC2)NC(Nc(cc3Cl)ccc3F)=O)C[C@@]12c(cc1OC)ccc1OC KZAPNQXZXCIUIN-OSWMTFESSA-N 0.000 description 1
- XRDJOZIZRAORNQ-FPGHNAPASA-N CN(C[C@H]1C[C@@H](CC2)NC(c(cc3)ccc3F)=O)C[C@@]12c(cc1OC)ccc1OC Chemical compound CN(C[C@H]1C[C@@H](CC2)NC(c(cc3)ccc3F)=O)C[C@@]12c(cc1OC)ccc1OC XRDJOZIZRAORNQ-FPGHNAPASA-N 0.000 description 1
- DHUVHACCCOWPME-REHUZNOOSA-N CN(C[C@H]1C[C@@H](CC2)NC(c3ccc(C(F)(F)F)cc3)=O)C[C@@]12c(cc1OC)ccc1OC Chemical compound CN(C[C@H]1C[C@@H](CC2)NC(c3ccc(C(F)(F)F)cc3)=O)C[C@@]12c(cc1OC)ccc1OC DHUVHACCCOWPME-REHUZNOOSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241001468045 Channa Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229910020323 ClF3 Inorganic materials 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000029828 Melanin-concentrating hormone receptor Human genes 0.000 description 1
- 108010047068 Melanin-concentrating hormone receptor Proteins 0.000 description 1
- 241001132506 Mesembryanthemum expansum Species 0.000 description 1
- 235000019119 Mesembryanthemum tortuosum Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241000233805 Phoenix Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 230000001539 anorectic effect Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000732 arylene group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 201000011529 cardiovascular cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- MPTQRFCYZCXJFQ-UHFFFAOYSA-L copper(II) chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Cu+2] MPTQRFCYZCXJFQ-UHFFFAOYSA-L 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 235000021130 excess caloric intake Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000035611 feeding Effects 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000001639 hypophagic effect Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- SEEYREPSKCQBBF-UHFFFAOYSA-N n-methylmaleimide Chemical compound CN1C(=O)C=CC1=O SEEYREPSKCQBBF-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- YCWSUKQGVSGXJO-NTUHNPAUSA-N nifuroxazide Chemical group C1=CC(O)=CC=C1C(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 YCWSUKQGVSGXJO-NTUHNPAUSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- 229950000964 pepstatin Drugs 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000001337 psychedelic effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000001725 pyrenyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Definitions
- the present invention relates to substituted octahydroisoindoles that act as antagonist for the melanin concentrating hormone receptor 1 (MCHlR).
- MCHlR melanin concentrating hormone receptor 1
- the invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of obesity as well as method of treatment of these disorders.
- MCH Melanin Concentrating Hormone
- mice lacking MCH are hypophagic and lean, and have increased energy expenditure (20 % increase over control animals when expressed on a per kg basis) (Shimada M et al., Nature, 1998; 396(6712):670-4).
- Studies of transgenic mice overexpressing MCH in the lateral hypothalamus show that these animals are more prone to diet-induced obesity when fed a high fat diet, and they have higher systemic leptin levels (Ludwig DS et al., J.
- Obesity is linked to a wide range of medical complications, such as diabetes, cardiovascular disease and cancer. In addition, being overweight can exacerbate the development of osteoporosis and asthma. For example, at least 75% of Type II diabetics are overweight and a clear correlation has been demonstrated between weight and the prevalence of Type II diabetes. Obesity is also proven to double the risk of hypertension. It is estimated that between 2% and 8% of total health-care costs in the Western world are related to obesity, i.e. in excess of 10 billion USD. Initial treatment for obesity is simple diet and exercise. Initial drug therapy tends to be focused around suppression of appetite. Many of the older appetite- suppressant agents act via the noradrenergic (and possibly dopaminergic) receptors to produce a feeling of satiety.
- Amphetamine was the archetypal agent in this class, but it has substantial potential for stimulating the central nervous system and consequent abuse. More recent developments, such as Xenical (orlistat), marketed by Roche, have focused on preventing fat absorption in the gut. Xenical inhibits the action of the enzyme lipases, thereby reducing the digestion of triglycerides and subsequent absorption by the intestinal tract. Unfortunately, this does not address overeating and excess calorie intake. Other pharmacological approaches for the treatment of obesity include serotonin re-uptake inhibitors, such as Reductil (sibutramine) marketed by Abbot, which acts as an appetite- suppressant.
- Reductil sibutramine
- MCHlR antagonists for the treatment of obesity.
- Several excellent reviews have been written: Carpenter and Hertzog, Expert Opin. Ther. Patents, 2002, 12(11): 1639-1646, Collins and Kym, Curr. Opin. In Invest. Drugs, 2003, 4(4): 386-394, Browning, Expert Opin. Ther. Patents, 2004, 14(3): 313-325 and Kowalski and McBriar, Expert Opin. Investig. Drugs, 2004, 13(9): 1113-1122 WO01/21169 (Takeda Chemical Industries) describes diaryl compounds as MCH-IR antagonists useful for the treatment of obesity.
- JP 13226269 (Takeda), describing several piperidine-substituted benzazepines and benzazepinones; WO01/82925 (Takeda), disclosing different amines; and WO01/87834 (Takeda) describing piperidine compound with benzene (1:1), claim compounds for the treatment of obesity.
- WO01/21577 discloses a series of amines claimed to be anorectic, antidiabetic and antidepressant agents.
- WO01/57070 (Merck) describes in a series of truncated and modified peptidic MCH analogues as either significant agonist or antagonist activity.
- MCH-IR antagonists for the treatment of feeding disorders, such as obesity and bulimia
- WO02/051809 Schering Corporation
- 4-substituted piperidine derivatives are disclosed as MCH antagonists as well as their use in the treatment of obesity.
- aryl- substituted ureas are disclosed as MCH antagonists as well as their use in the treatment of obesity.
- the central core in the WO02/057233 is a(n) (hetero)arylene group, whereas the central core in the present compounds is an octahydroisoindole group.
- PCT/SE2004/001619 and PCT/SE2004/001620 disclose octahydroindoles that act as antagonists for the melanin concentrating hormone receptor 1 (MCHlR).
- MCHlR melanin concentrating hormone receptor 1
- Mesembrine, 3a-(3,4-dimethoxyphenyl)-l-methyloctahydro-6H-indol-6-one is a natural product obtained as an extract of plants of the Mesembryanthemaceae family, including Sceletium tortuosum. In small doses the mesembrine extracts have a meditative or narcotic effect. Hottentots used Sceletium expansum and tortuosum as a psychedelic called "channa". The use of mesembrine as a serotonin-uptake inhibitor for the treatment of an array of mental disorders is disclosed in WO97/46234.
- novel substituted octahydroisoindoles have been found that are active towards the MCHlR receptor.
- the compounds are relatively easy to prepare and can be used for the treatment or prevention of obesity, diabetes mellitus, hyperlipidemia, hyperglycemia, modulation of appetite, depression, anxiety or urinary incontinence.
- the compounds can further be used in conjunction with other compounds acting through other mechanisms, such as MC-4 agonists, 5HT 2c agonists, or 5HT 6 antagonists.
- the compounds can also be used in conjunction with anti-obesity medicaments.
- Ci-6-alkyl denotes a straight or branched alkyl group having from 1 to 6 carbon atoms.
- examples of said lower alkyl include methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl and straight- and branched-chain pentyl and hexyl.
- Ci- 5 -alkyl Ci- 4 -alkyl
- Q- 3 -alkyl Ci_ 2 -alkyl
- Ci_ 2 -alkyl C 2 .
- Halo-Q-e-alkyl means a Q- 6 -alkyl group substituted by one or more halogen atoms.
- Ci-6-alkoxy denotes a straight or branched alkoxy group having from 1 to 6 carbon atoms.
- examples of said lower alkoxy include methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, sec-butoxy, t- butoxy and straight- and branched-chain pentoxy and hexoxy.
- Q_ 6 - alkoxy For parts of the range "Q_ 6 - alkoxy" all subgroups thereof are contemplated such as Q-5-alkoxy, Q-4-alkoxy, C 1-3 - alkoxy, Ci ⁇ -alkoxy, C 2 _6-alkoxy, C 2 _5-alkoxy, C 2 _ 4 -alkoxy, C 2 _ 3 -alkoxy, C 3 _6-alkoxy, C4-5- alkoxy, etc.
- "Halo-Ci-6-alkoxy” means a Q-6-alkoxy group substituted by one or more halogen atoms.
- halogen shall mean fluorine, chlorine, bromine or iodine.
- aryl refers to a hydrocarbon ring system having at least one aromatic ring.
- aryls are phenyl, pentalenyl, indenyl, dihydroindenyl, isoindolinyl, chromanyl, naphthyl, fluorenyl, anthryl, phenanthryl and pyrenyl.
- the aryl rings may optionally be substituted by Ci-6-alkyl. Examples of substituted aryl groups are benzyl and 2-methylphenyl.
- heteroaryl refers to a hydrocarbon ring system having at least one aromatic ring which contains at least one heteroatom such as O, N, or S.
- heteroaryl groups include furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, quinazolinyl, indolyl, pyrazolyl, pyridazinyl, quinolinyl, quinoxalinyl, thiadiazolyl, benzofuranyl, 2,3-dihydrobenzofuranyl, benzodioxolyl, benzodioxinyl, 2,3-dihydro-l,4-benzodioxinyl, benzothiazolyl, benzothiadiazolyl, and benzotriazolyl groups.
- Coupled agent refers to a compound used when coupling together an amine and a carboxylic acid.
- An example of a coupling agent is l-[3-
- “Pharmaceutically acceptable” means being useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes being useful for veterinary use as well as human pharmaceutical use.
- Treatment includes prophylaxis of the named disorder or condition, or amelioration or elimination of the disorder once it has been established.
- An effective amount refers to an amount of a compound that confers a therapeutic effect on the treated subject.
- the therapeutic effect may be objective (i.e., measurable by some test or marker) or subjective (i.e., subject gives an indication of or feels an effect).
- prodrug forms means a pharmacologically acceptable derivative, such as an ester or an amide, which derivative is biotransformed in the body to form the active drug.
- pharmacologically acceptable derivative such as an ester or an amide
- halo-Q- 6 -alkyl means a Q- 6 -alkyl group that is substituted by one or more halogen atoms.
- halo-Ci-6-alkylthio means a Ci-6-alkylthio group that is substituted by one or more halogen atoms.
- DCM dichloromethane
- DMF means dimethylformamide
- i-PrOH means isopropanol
- HPLC means high performance liquid chromatography
- HRMS means high resolution mass spectrometry
- R.T. (rt.) room temperature
- TEA trifluoroacetic acid
- THF tetrahydrofuran
- the present invention provides a compound of the general formula (I)
- X is NH or a single bond
- Ar is aryl, wherein the aryl may be substituted by one or more of C ⁇ -alkoxy;
- R 1 is Ci-6-alkyl
- R 2 is H
- R 3 is selected from aryl optionally substituted by one or more of halogen, cyano, halo-Ci-6- alkylthio, Ci_ 6 -alkoxy, Ci_ 6 -alkyl, halo-C ⁇ ⁇ -alkyl; and heteroaryl optionally substituted by one or more of halogen.
- Ar is selected from phenyl, wherein the phenyl may be substituted by one or more of Ci_6-alkoxy, especially by one or more of methoxy. Most preferably, Ar is 3,4-dimethoxyphenyl. It is preferred that R 1 is methyl. It is preferred that R 3 is selected from phenyl optionally substituted by one or more of bromo, chloro, cyano, (difluoromethyl)thio, fluoro, iodo, methoxy, methyl, trifluoromethyl, (trifluoromethyl)thio; l,3-benzodioxol-5-yl optionally substituted by one or more of fluoro; and pyridyl.
- R 3 is selected from 4-bromo-3-methylphenyl, 3- bromophenyl, 4-bromophenyl, 4-bromo-2-(trifluoromethyl)phenyl, 3-chloro-2- fluorophenyl, 3-chloro-4-fluorophenyl, 3-chlorophenyl, 4-chlorophenyl, 4-chloro-3-
- Another object of the present invention is a process for the preparation of a compound above comprising at least one of the following steps:
- Another object of the present invention is a compound as described above for use in therapy.
- the compound can be used in the treatment or prophylaxis of obesity, diabetes mellitus, hyperlipidemia, hyperglycemia, depression, anxiety, urinary incontinence, and for modulation of appetite. It may also be used in the treatment or prophylaxis of disorders relating to the MCHlR receptor and for modulation of appetite. Examples of such disorders are obesity, diabetes mellitus, hyperlipidemia, hyperglycemia, depression, anxiety, and urinary incontinence.
- the compound can further be used in conjunction with other compounds active towards other receptors, such as MC-4 agonists, 5HT 2c agonists, or 5HT 6 antagonists.
- the compound can also be used in conjunction with anti-obesity medicaments.
- Another object of the present invention is a pharmaceutical formulation containing a compound as described above as an active ingredient, in combination with a pharmaceutically acceptable diluent or carrier.
- the pharmaceutical formulation may be used in the treatment or prophylaxis of obesity wherein the active ingredient is a compound as described above.
- Another object of the present invention is a method for the treatment or prophylaxis of obesity, diabetes mellitus, hyperlipidemia, hyperglycemia, depression, anxiety, urinary incontinence, and for modulation of appetite, said method comprising administering to a subject (e.g., mammal, human, or animal) in need of such treatment an effective amount of a compound as described above.
- a subject e.g., mammal, human, or animal
- the compound can further be used in conjunction with other compounds active towards other receptors, such as MC-4 agonists, 5HT 2c agonists, or 5HT 6 antagonists.
- the compound can also be used in conjunction with anti-obesity medicaments.
- Another object of the present invention is a method for the treatment or prophylaxis of disorders related to the MCHlR receptor and for modulation of appetite, said method comprising administering to a subject (e.g., mammal, human, or animal) in need of such treatment an effective amount of a compound as described above.
- the MCHlR receptor related disorder is any disorder or symptom wherein the MCHlR receptor is involved in the process or presentation of the disorder or the symptom.
- the MCHlR related disorders include, but are not limited to obesity, diabetes mellitus, hyperlipidemia, hyperglycemia, depression, anxiety, and urinary incontinence.
- the compound can further be used in conjunction with other compounds active towards other receptors, such as MC-4 agonists, 5HT 2c agonists, or 5HT 6 antagonists.
- the compound can also be used in conjunction with anti-obesity medicaments.
- Another object of the present invention is a method for modulating MCHlR receptor activity (e.g., antagonizing the human MCHlR receptor), comprising administering to a subject (e.g., mammal, human, or animal) in need thereof an effective amount of a compound as described above or a composition comprising a compound as described above.
- a subject e.g., mammal, human, or animal
- Another object of the present invention is the use of a compound as described above in the manufacture of a medicament for use in the treatment or prophylaxis of obesity, diabetes mellitus, hyperlipidemia, hyperglycemia, depression, anxiety, and urinary incontinence, and for modulation of appetite.
- Another object of the present invention is the use of a compound as described above in the manufacture of a medicament for use in the treatment or prophylaxis of disorders related to the MCHlR receptor and for modulation of appetite, said method comprising administering to a subject (e.g., mammal, human, or animal) in need of such treatment an effective amount of a compound as described above.
- the MCHlR receptor related disorder is any disorder or symptom wherein the MCHlR receptor is involved in the process or presentation of the disorder or the symptom.
- the MCHlR related disorders include, but are not limited to obesity, diabetes mellitus, hyperlipidemia, hyperglycemia, depression, anxiety, and urinary incontinence.
- the compound can further be used in conjunction with other compounds active towards other receptors, such as MC-4 agonists, 5HT 2c agonists, or 5HT 6 antagonists.
- the compound can also be used in conjunction with anti-obesity medicaments.
- the compounds of the formula (I) may be used as such or, where appropriate, as pharmacologically acceptable salts (acid or base addition salts) thereof.
- pharmacologically acceptable addition salts mentioned above are meant to comprise the therapeutically active non-toxic acid and base addition salt forms that the compounds are able to form.
- Compounds that have basic properties can be converted to their pharmaceutically acceptable acid addition salts by treating the base form with an appropriate acid.
- Exemplary acids include inorganic acids, such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulfuric acid, phosphoric acid; and organic acids such as formic acid, acetic acid, propanoic acid, hydroxyacetic acid, lactic acid, pyruvic acid, glycolic acid, maleic acid, malonic acid, oxalic acid, benzenesulfonic acid, toluenesulfonic acid, methanesulfonic acid, trifluoroacetic acid, fumaric acid, succinic acid, malic acid, tartaric acid, citric acid, salicylic acid, p-aminosalicylic acid, pamoic acid, benzoic acid, ascorbic acid and the like.
- organic acids such as formic acid, acetic acid, propanoic acid, hydroxyacetic acid, lactic acid, pyruvic acid, glycolic acid, maleic acid, malonic acid, oxalic acid, benzenesulfonic acid, tolu
- Exemplary base addition salt forms are the sodium, potassium, calcium salts, and salts with pharmaceutically acceptable amines such as, for example, ammonia, alkylamines, benzathine, and amino acids, such as, e.g. arginine and lysine.
- the term addition salt as used herein also comprises solvates which the compounds and salts thereof are able to form, such as, for example, hydrates, alcoholates and the like.
- the compounds of the invention are formulated into pharmaceutical formulations for oral, rectal, parenteral or other mode of administration.
- Pharmaceutical formulations are usually prepared by mixing the active substance, or a pharmaceutically acceptable salt thereof, with conventional pharmaceutical excipients.
- excipients are water, gelatin, gum arabicum, lactose, microcrystalline cellulose, starch, sodium starch glycolate, calcium hydrogen phosphate, magnesium stearate, talcum, colloidal silicon dioxide, and the like.
- Such formulations may also contain other pharmacologically active agents, and conventional additives, such as stabilizers, wetting agents, emulsifiers, flavouring agents, buffers, and the like.
- the formulations can be further prepared by known methods such as granulation, compression, microencapsulation, spray coating, etc.
- the formulations may be prepared by conventional methods in the dosage form of tablets, capsules, granules, powders, syrups, suspensions, suppositories or injections.
- Liquid formulations may be prepared by dissolving or suspending the active substance in water or other suitable vehicles. Tablets and granules may be coated in a conventional manner.
- the invention relates to methods of making compounds of any of the formulae herein comprising reacting any one or more of the compounds of the formulae delineated herein, including any processes delineated herein.
- the compounds of the formula (I) above may be prepared by, or in analogy with, conventional methods. The processes described above may be carried out to give a compound of the invention in the form of a free base or as an acid addition salt.
- a pharmaceutically acceptable acid addition salt may be obtained by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. Examples of addition salt forming acids are mentioned above.
- the compounds of formula (I) may possess one or more chiral carbon atoms, and they may therefore be obtained in the form of optical isomers, e.g. as a pure enantiomer, or as a mixture of enantiomers (racemate) or as a mixture containing diastereomers.
- optical isomers e.g. as a pure enantiomer, or as a mixture of enantiomers (racemate) or as a mixture containing diastereomers.
- the separation of mixtures of optical isomers to obtain pure enantiomers is well known in the art and may, for example, be achieved by fractional crystallization of salts with optically active (chiral) acids or by chromatographic separation on chiral columns.
- the necessary starting materials for preparing the compounds of formula (I) are either known or may be prepared in analogy with the preparation of known compounds.
- the dose level and frequency of dosage of the specific compound will vary depending on a variety of factors including the potency of the specific compound employed, the metabolic stability and length of action of that compound, the patient's age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the condition to be treated, and the patient undergoing therapy.
- the daily dosage may, for example, range from about 0.001 mg to about 100 mg per kilo of body weight, administered singly or multiply in doses, e.g. from about 0.01 mg to about 25 mg each. Normally, such a dosage is given orally but parenteral administration may also be chosen.
- COMPARATIVE EXAMPLE 1 3-f3,4-dimethoxyphenyl)-l-methyl-lH-pyrrole-2,5- dione
- Triphosgene (17 mg, 0.058 mmol) in DCM (1 mL) was, added dropwise under N 2 , to a solution of (3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5- amine, prepared in comparative example 6, (42 mg, 0.14 mmol) and dry NEt 3 (40 ⁇ L, 0.28 mmol) in DCM (2 mL).
- the solution was stirred at rt. for 3 hours, then 3,4,5- trifluoroaniline (21 mg, 0.14 mmol) was added and stirring continued over night.
- EXAMPLE 52 and EXAMPLE 53 N-r(3aS,5R,7aR)-7a-(3,4-dimethoxyphenyl)-2- methyloctahydro-lH-isoindol-5-yl1-3-fluoro-4-(trifluoromethyl)benzamide trifluoroacetate and N-rf3aR,5S,7aS)-7a-f3,4-dimethoxyphenyl)-2-methyloctahvdro-lH-isoindol-5-yl1-3- fluoro-4-(trifluoromethyl)benzamide trifluoroacetate
- the active ingredient 1 is mixed with ingredients 2, 3, 4 and 5 for about 10 minutes.
- the magnesium stearate is then added, and the resultant mixture is mixed for about 5 minutes and compressed into tablet form with or without film-coating.
- BIOLOGICAL METHODS The ability of a compound of the invention to bind or act at the MCHlR receptor can be determined using in vitro and in vivo assays known in the art.
- the compounds according to the invention were evaluated for their binding to the human MCHlR receptor by the following method:
- MCH peptide was purchased from Phoenix pharmaceuticals. (Phe 13 , [ 125 I]Tyr 19 Melanine-Concentrating Hormone (human, mouse, rat) ([ 125 I]-MCH) was obtained from NEN life Science Products. Inc. Boston, MA. Wheat germ agglutinine SPA beads (RPNQ 0001) were obtained from Amersham-Pharmacia Biotech. All other reagents used are of highest purity from different resources available. Protein Kits, Micro BCATM Protein Assay Reagent Kit (Cat No. 23235) were purchased from Piece, Rockford, IL, USA. Plastic wares: Cell culture flasks, dishes were from Decton Dickinson Labware, NJ, USA. Scintillation plate, white clear bottom were from Wallac, Finland.
- the homogenized preparation was centrifuged at 40,00Og (18500 rpm with ss-34, No. 5 rotor in Sorvall centrifuge, RC5C, DuPont) for 25 minutes at 4 °C.
- the pellets were washed once with Buffer A and centrifuged again under the same conditions.
- the pellets were suspended with Buffer B, which contains Tris.HCl (7.5), MgCl 2 .6H 2 O (12.5), EDTA (0.3), EGTA (1), sucrose (25) in mM with pH 7.5, and gently homogenized for several times with a glass homogenizer.
- Buffer B which contains Tris.HCl (7.5), MgCl 2 .6H 2 O (12.5), EDTA (0.3), EGTA (1), sucrose (25) in mM with pH 7.5, and gently homogenized for several times with a glass homogenizer.
- the membrane preparation was aliquoted into Eppendorf tubes, 1 ml/tube and frozen
- the WGA beads were re-constituted with reaction buffer, which contains Tris (50), MgCl 2 (5), EDTA (2.5) in mM with pH adjusted to 7.4, to 40 mg/ml as a stock suspension.
- reaction buffer which contains Tris (50), MgCl 2 (5), EDTA (2.5) in mM with pH adjusted to 7.4, to 40 mg/ml as a stock suspension.
- the beads and the membrane will be pre-incubated with for 30 minutes at room temperature with gentle shaking.
- the suspension of the beads was centrifuged at 3400 rpm for 2 minutes using centrifuge.
- the supernatant was discarded and the beads were re-suspended with binding buffer, HEPES (25mM), MgCl 2 (5mM), CaCl 2 (ImM), BSA (0.5%) with peptidase inhibitors (l ⁇ g/ml) Leupeptin, Aprotinin and pepstatin, pH 7.4.
- the radio labeled [ 125 I]-MCH was diluted with cold MCH in ratio 1:3. In Kd determination, the concentrations of labeled peptide were 3 nM with 1:2 series dilution for 11 samples. The amount of the beads was 0.25 mg/well. The results were calculated using Excel program and the curves were drawn using a program GraphPad Prism.
- the amount of the beads used was 0.25 mg/well and the amount of the membrane protein was 4 ⁇ g/well.
- 0.2 nM [ I]-MCH was used for total binding and 300 nM MCH used as non-specific binding.
- the total volume was 200 ⁇ l, which contained 50 ⁇ l [ I]-MCH, 100 ⁇ l substances and 50 ⁇ l beads.
- the plate was gently shaken for 30 minute and incubated overnight.
- the samples were counted using Microbeta counter (Wallac Trilux 1450 Micro beta counter, Wallac, Finland) for 2 minutes and the results were calculated by using the computer program Activity Base.
- K 1 IC 50 (l+[S]/K m ) [Cheng, Y.C.; Prushoff, W.H. Biochem. Pharmacol. 1973, 22, 3099-3108].
- the compounds of formula (I) exhibit the IC50 values for the MCHlR receptor in the range from 1 nM to 10 ⁇ M.
- the following Ki values have been determined in the assay (see Table 1):
- Table 1 Ki values determined in the assay.
Abstract
The invention relates to compounds of the general formula (I) wherein R1, R2, R3, Ar, and X are as defined herein, or a pharmaceutically acceptable salt, hydrates, geometrical isomers, racemates, tautomers, optical isomers, N-oxides and prodrug forms thereof. The compounds may be used for the treatment or prophylaxis of disorders related to the MCH1R receptor and for modulation of appetite. The invention also relates to such use as well as to pharmaceutical formulations comprising a compound of formula (I).
Description
SUBSTITUTED OCTAHYDROISOINDOLES AS ANTAGONISTS OF MELANIN CONCENTRATING HORMONE RECEPTOR 1 (MCHlR)
TECHNICAL FIELD
The present invention relates to substituted octahydroisoindoles that act as antagonist for the melanin concentrating hormone receptor 1 (MCHlR). The invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the preparation of a medicament for the prophylaxis and treatment of obesity as well as method of treatment of these disorders.
BACKGROUND ART
Melanin Concentrating Hormone (MCH) is a 19 AA cyclic peptide, which is expressed in hypothalamus in the mammalian brain (Nahon JL et al., Endocrinology, 1989; 125(4):2056-65 and Tritos NA, et al., Diabetes, 1998; 47(11): 1687-92). A substantial body of evidence has shown that this peptide plays a critical role in the moderation of feeding behavior and energy expenditure. Studies have shown that ICV administration of MCH directly into rat brains results in a marked increase in food intake ( Ludwig DS et al., Am. J. Physiol, 1998; 274(4 Pt l):E627-33). It has also been shown that messenger RNA for the MCH precursor is up-regulated in the hypothalamus of fasted animals and in animals that are genetically obese (Qu D, Ludwig DS et al., Nature, 1996; 380(6571):243-7). Furthermore, mice lacking MCH are hypophagic and lean, and have increased energy expenditure (20 % increase over control animals when expressed on a per kg basis) (Shimada M et al., Nature, 1998; 396(6712):670-4). Studies of transgenic mice overexpressing MCH in the lateral hypothalamus show that these animals are more prone to diet-induced obesity when fed a high fat diet, and they have higher systemic leptin levels (Ludwig DS et al., J. Clin. Invest, 2001; 107(3):379-86). Blood glucose levels were increased both preprandially and after intraperitoneal injection of glucose. The animals also had increased insulin levels and insulin tolerance test indicated peripheral insulin resistance. Further support for the role of MCH in metabolic regulation comes from studies showing that, in mice, mRNA for the MCH receptor is upregulated 7-fold by 48h fasting and in genetic leptin deficiency (ob/ob mice). These effects could be completely blunted by leptin treatment (Kokkotou EG et al., Endocrinology, 2001; 142(2):680-6.). In addition to its role in regulating feeding behavior, MCH antagonists have been demonstrated to have i
anxiolytic and antidepressant effects (Borowsky, BD et al., Nature Medicine, 2002. 8(8): 825-830).
Obesity is linked to a wide range of medical complications, such as diabetes, cardiovascular disease and cancer. In addition, being overweight can exacerbate the development of osteoporosis and asthma. For example, at least 75% of Type II diabetics are overweight and a clear correlation has been demonstrated between weight and the prevalence of Type II diabetes. Obesity is also proven to double the risk of hypertension. It is estimated that between 2% and 8% of total health-care costs in the Western world are related to obesity, i.e. in excess of 10 billion USD. Initial treatment for obesity is simple diet and exercise. Initial drug therapy tends to be focused around suppression of appetite. Many of the older appetite- suppressant agents act via the noradrenergic (and possibly dopaminergic) receptors to produce a feeling of satiety. Amphetamine was the archetypal agent in this class, but it has substantial potential for stimulating the central nervous system and consequent abuse. More recent developments, such as Xenical (orlistat), marketed by Roche, have focused on preventing fat absorption in the gut. Xenical inhibits the action of the enzyme lipases, thereby reducing the digestion of triglycerides and subsequent absorption by the intestinal tract. Unfortunately, this does not address overeating and excess calorie intake. Other pharmacological approaches for the treatment of obesity include serotonin re-uptake inhibitors, such as Reductil (sibutramine) marketed by Abbot, which acts as an appetite- suppressant.
The concept of using MCHlR antagonists for the treatment of obesity has recently been published. Several excellent reviews have been written: Carpenter and Hertzog, Expert Opin. Ther. Patents, 2002, 12(11): 1639-1646, Collins and Kym, Curr. Opin. In Invest. Drugs, 2003, 4(4): 386-394, Browning, Expert Opin. Ther. Patents, 2004, 14(3): 313-325 and Kowalski and McBriar, Expert Opin. Investig. Drugs, 2004, 13(9): 1113-1122 WO01/21169 (Takeda Chemical Industries) describes diaryl compounds as MCH-IR antagonists useful for the treatment of obesity. Also JP 13226269 (Takeda), describing several piperidine-substituted benzazepines and benzazepinones; WO01/82925 (Takeda), disclosing different amines; and WO01/87834 (Takeda) describing piperidine compound with benzene (1:1), claim compounds for the treatment of obesity. WO01/21577 (Takeda) discloses a series of amines claimed to be anorectic, antidiabetic and antidepressant agents. WO01/57070 (Merck) describes in a series of truncated and modified peptidic MCH analogues as either significant agonist or antagonist activity. In WO02/10146
(GlaxoSmithKline) the preparation of carboxamide compounds claimed for the treatment of obesity as well as diabetes, depression and anxiety is disclosed. WO02/04433 (The Neurogen Corporation) describes in N-arylpiperazine derivatives and related A- arylpiperidine derivatives as selective modulators of MCH-IR for the treatment of a variety of metabolic, feeding and sexual disorders. In WO02/06245 (Synaptic
Pharmaceutical Corporation) a class of dihydropyrimidinones as MCH-IR antagonists for the treatment of feeding disorders, such as obesity and bulimia is disclosed. In WO02/051809 (Schering Corporation) 4-substituted piperidine derivatives are disclosed as MCH antagonists as well as their use in the treatment of obesity. In WO02/057233 aryl- substituted ureas are disclosed as MCH antagonists as well as their use in the treatment of obesity. The central core in the WO02/057233 is a(n) (hetero)arylene group, whereas the central core in the present compounds is an octahydroisoindole group. PCT/SE2004/001619 and PCT/SE2004/001620 disclose octahydroindoles that act as antagonists for the melanin concentrating hormone receptor 1 (MCHlR). Mesembrine, 3a-(3,4-dimethoxyphenyl)-l-methyloctahydro-6H-indol-6-one, is a natural product obtained as an extract of plants of the Mesembryanthemaceae family, including Sceletium tortuosum. In small doses the mesembrine extracts have a meditative or narcotic effect. Hottentots used Sceletium expansum and tortuosum as a psychedelic called "channa". The use of mesembrine as a serotonin-uptake inhibitor for the treatment of an array of mental disorders is disclosed in WO97/46234.
US 6,288,104 discloses mesembrine-like compounds lacking the urea or amide group in the present compounds. This document relates to serotonin-uptake inhibitors for the treatment of depression and anxiety, whereas the present compounds are antagonists for the MCH-IR. None of the above disclosures discloses the compounds according to the present invention as antagonists for the MCH-IR.
DISCLOSURE OF THE INVENTION
According to the present invention, novel substituted octahydroisoindoles have been found that are active towards the MCHlR receptor. The compounds are relatively easy to prepare and can be used for the treatment or prevention of obesity, diabetes mellitus, hyperlipidemia, hyperglycemia, modulation of appetite, depression, anxiety or urinary incontinence. The compounds can further be used in conjunction with other
compounds acting through other mechanisms, such as MC-4 agonists, 5HT2c agonists, or 5HT6 antagonists. The compounds can also be used in conjunction with anti-obesity medicaments.
Definitions
The following definitions shall apply throughout the specification and the appended claims.
Unless otherwise stated or indicated, the term "Ci-6-alkyl" denotes a straight or branched alkyl group having from 1 to 6 carbon atoms. Examples of said lower alkyl include methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, t-butyl and straight- and branched-chain pentyl and hexyl. For parts of the range "Ci-6-alkyl" all subgroups thereof are contemplated such as Ci-5-alkyl, Ci-4-alkyl, Q-3-alkyl, Ci_2-alkyl, C2. 6-alkyl, C2_5-alkyl, C2_4-alkyl, C2_3-alkyl, C3_6-alkyl, C4-5-alkyl, etc. "Halo-Q-e-alkyl" means a Q-6-alkyl group substituted by one or more halogen atoms.
Unless otherwise stated or indicated, the term "Ci-6-alkoxy" denotes a straight or branched alkoxy group having from 1 to 6 carbon atoms. Examples of said lower alkoxy include methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, sec-butoxy, t- butoxy and straight- and branched-chain pentoxy and hexoxy. For parts of the range "Q_6- alkoxy" all subgroups thereof are contemplated such as Q-5-alkoxy, Q-4-alkoxy, C1-3- alkoxy, Ci^-alkoxy, C2_6-alkoxy, C2_5-alkoxy, C2_4-alkoxy, C2_3-alkoxy, C3_6-alkoxy, C4-5- alkoxy, etc. "Halo-Ci-6-alkoxy" means a Q-6-alkoxy group substituted by one or more halogen atoms.
Unless otherwise stated or indicated, the term "halogen" shall mean fluorine, chlorine, bromine or iodine.
Unless otherwise stated or indicated, the term "aryl" refers to a hydrocarbon ring system having at least one aromatic ring. Examples of aryls are phenyl, pentalenyl, indenyl, dihydroindenyl, isoindolinyl, chromanyl, naphthyl, fluorenyl, anthryl, phenanthryl and pyrenyl. The aryl rings may optionally be substituted by Ci-6-alkyl. Examples of substituted aryl groups are benzyl and 2-methylphenyl.
The term "heteroaryl" refers to a hydrocarbon ring system having at least one aromatic ring which contains at least one heteroatom such as O, N, or S. Examples of heteroaryl groups include furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, thiazolyl, isothiazolyl, pyridyl, pyrimidinyl, quinazolinyl, indolyl, pyrazolyl, pyridazinyl,
quinolinyl, quinoxalinyl, thiadiazolyl, benzofuranyl, 2,3-dihydrobenzofuranyl, benzodioxolyl, benzodioxinyl, 2,3-dihydro-l,4-benzodioxinyl, benzothiazolyl, benzothiadiazolyl, and benzotriazolyl groups.
The term "coupling agent" refers to a compound used when coupling together an amine and a carboxylic acid. An example of a coupling agent is l-[3-
(dimethylaminopropyl)]-3-ethylcarbodiimide hydrochloride, which is used in the presence of hydroxybenzotriazole and a base such as triethylamine.
"Pharmaceutically acceptable" means being useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes being useful for veterinary use as well as human pharmaceutical use.
"Treatment" as used herein includes prophylaxis of the named disorder or condition, or amelioration or elimination of the disorder once it has been established.
"An effective amount" refers to an amount of a compound that confers a therapeutic effect on the treated subject. The therapeutic effect may be objective (i.e., measurable by some test or marker) or subjective (i.e., subject gives an indication of or feels an effect).
The term "prodrug forms" means a pharmacologically acceptable derivative, such as an ester or an amide, which derivative is biotransformed in the body to form the active drug. Reference is made to Goodman and Gilman's, The Pharmacological basis of
Therapeutics, 8th ed., Mc-Graw-Hill, Int. Ed. 1992, "Biotransformation of Drugs", p. 13- 15.
When two of the above-mentioned terms are used together, it is intended that the latter group is substituted by the former. For example, halo-Q-6-alkyl means a Q-6-alkyl group that is substituted by one or more halogen atoms. Likewise, halo-Ci-6-alkylthio means a Ci-6-alkylthio group that is substituted by one or more halogen atoms.
The following abbreviations have been used:
DCM means dichloromethane,
DMF means dimethylformamide, i-PrOH means isopropanol,
HPLC means high performance liquid chromatography,
HRMS means high resolution mass spectrometry,
R.T. (rt.) means room temperature,
TEA means trifluoroacetic acid,
THF means tetrahydrofuran.
In a first aspect, the present invention provides a compound of the general formula (I)
or a pharmaceutically acceptable salt, hydrates, geometrical isomers, racemates, tautomers, optical isomers, N-oxides and prodrug forms thereof, wherein:
X is NH or a single bond; Ar is aryl, wherein the aryl may be substituted by one or more of C^-alkoxy;
R1 is Ci-6-alkyl;
R2 is H;
R3 is selected from aryl optionally substituted by one or more of halogen, cyano, halo-Ci-6- alkylthio, Ci_6-alkoxy, Ci_6-alkyl, halo-C^ό-alkyl; and heteroaryl optionally substituted by one or more of halogen.
It is preferred that Ar is selected from phenyl, wherein the phenyl may be substituted by one or more of Ci_6-alkoxy, especially by one or more of methoxy. Most preferably, Ar is 3,4-dimethoxyphenyl. It is preferred that R1 is methyl. It is preferred that R3 is selected from phenyl optionally substituted by one or more of bromo, chloro, cyano, (difluoromethyl)thio, fluoro, iodo, methoxy, methyl, trifluoromethyl, (trifluoromethyl)thio; l,3-benzodioxol-5-yl optionally substituted by one or more of fluoro; and pyridyl.
It is more preferred that R3 is selected from 4-bromo-3-methylphenyl, 3- bromophenyl, 4-bromophenyl, 4-bromo-2-(trifluoromethyl)phenyl, 3-chloro-2- fluorophenyl, 3-chloro-4-fluorophenyl, 3-chlorophenyl, 4-chlorophenyl, 4-chloro-3-
(trifluoromethyl)phenyl, 3-cyanophenyl, 4-cyanophenyl, 2,4-dichlorophenyl, 2,5- dichlorophenyl, 3,4-dichlorophenyl, 2,2-difluoro-l,3-benzodioxol-5-yl, 3-
(difluoromethyl)thiophenyl, 2,5-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 3,4-dimethoxyphenyl, 3,5-dimethylphenyl, 3-fluorophenyl, 4-fluorophenyl, 2-fluoro-3-
(trifluoromethyl)phenyl, 2-fluoro-4-(trifluoromethyl)phenyl, 3-fluoro-4-
(trifluoromethyl)phenyl, 3-fluoro-5-(trifluoromethyl)phenyl, 4-fluoro-3- (trifluoromethyl)phenyl, 4-iodophenyl, 2,3,4-trifluorophenyl, 3,4,5-trifluorophenyl, 3- (trifluoromethyl)phenyl, 4-(trifluoromethyl)phenyl, 4-(trifluoromethyl)thiophenyl, and A- pyridyl. Preferred compounds are denoted in Examples 7-29 and 31-56 below.
All diastereomeric forms possible (pure enantiomers, tautomers, racemic mixtures and unequal mixtures of two enantiomers) are within the scope of the invention. Such compounds can also occur as cis- or trans-, E- or Z- double bond isomer forms. All isomeric forms are contemplated. Another object of the present invention is a process for the preparation of a compound above comprising at least one of the following steps:
(a) acylation of an amine with a substituted benzoyl chloride,
(b) treatment of an amine with 4-carboxypyridine-N-oxide in the presence of a coupling agent, (c) treatment of an amine with a substituted aryl isocyanate, (d) treatment of an amine with triphosgene and another amine.
Another object of the present invention is a compound as described above for use in therapy. The compound can be used in the treatment or prophylaxis of obesity, diabetes mellitus, hyperlipidemia, hyperglycemia, depression, anxiety, urinary incontinence, and for modulation of appetite. It may also be used in the treatment or prophylaxis of disorders relating to the MCHlR receptor and for modulation of appetite. Examples of such disorders are obesity, diabetes mellitus, hyperlipidemia, hyperglycemia, depression, anxiety, and urinary incontinence. The compound can further be used in conjunction with other compounds active towards other receptors, such as MC-4 agonists, 5HT2c agonists, or 5HT6 antagonists. The compound can also be used in conjunction with anti-obesity medicaments.
Another object of the present invention is a pharmaceutical formulation containing a compound as described above as an active ingredient, in combination with a pharmaceutically acceptable diluent or carrier. The pharmaceutical formulation may be used in the treatment or prophylaxis of obesity wherein the active ingredient is a compound as described above.
Another object of the present invention is a method for the treatment or prophylaxis of obesity, diabetes mellitus, hyperlipidemia, hyperglycemia, depression, anxiety, urinary incontinence, and for modulation of appetite, said method comprising administering to a
subject (e.g., mammal, human, or animal) in need of such treatment an effective amount of a compound as described above. The compound can further be used in conjunction with other compounds active towards other receptors, such as MC-4 agonists, 5HT2c agonists, or 5HT6 antagonists. The compound can also be used in conjunction with anti-obesity medicaments.
Another object of the present invention is a method for the treatment or prophylaxis of disorders related to the MCHlR receptor and for modulation of appetite, said method comprising administering to a subject (e.g., mammal, human, or animal) in need of such treatment an effective amount of a compound as described above. The MCHlR receptor related disorder is any disorder or symptom wherein the MCHlR receptor is involved in the process or presentation of the disorder or the symptom. The MCHlR related disorders include, but are not limited to obesity, diabetes mellitus, hyperlipidemia, hyperglycemia, depression, anxiety, and urinary incontinence. The compound can further be used in conjunction with other compounds active towards other receptors, such as MC-4 agonists, 5HT2c agonists, or 5HT6 antagonists. The compound can also be used in conjunction with anti-obesity medicaments.
Another object of the present invention is a method for modulating MCHlR receptor activity (e.g., antagonizing the human MCHlR receptor), comprising administering to a subject (e.g., mammal, human, or animal) in need thereof an effective amount of a compound as described above or a composition comprising a compound as described above.
Another object of the present invention is the use of a compound as described above in the manufacture of a medicament for use in the treatment or prophylaxis of obesity, diabetes mellitus, hyperlipidemia, hyperglycemia, depression, anxiety, and urinary incontinence, and for modulation of appetite.
Another object of the present invention is the use of a compound as described above in the manufacture of a medicament for use in the treatment or prophylaxis of disorders related to the MCHlR receptor and for modulation of appetite, said method comprising administering to a subject (e.g., mammal, human, or animal) in need of such treatment an effective amount of a compound as described above. The MCHlR receptor related disorder is any disorder or symptom wherein the MCHlR receptor is involved in the process or presentation of the disorder or the symptom. The MCHlR related disorders include, but are not limited to obesity, diabetes mellitus, hyperlipidemia, hyperglycemia, depression, anxiety, and urinary incontinence. The compound can further be used in
conjunction with other compounds active towards other receptors, such as MC-4 agonists, 5HT2c agonists, or 5HT6 antagonists. The compound can also be used in conjunction with anti-obesity medicaments.
The compounds of the formula (I) may be used as such or, where appropriate, as pharmacologically acceptable salts (acid or base addition salts) thereof. The pharmacologically acceptable addition salts mentioned above are meant to comprise the therapeutically active non-toxic acid and base addition salt forms that the compounds are able to form. Compounds that have basic properties can be converted to their pharmaceutically acceptable acid addition salts by treating the base form with an appropriate acid. Exemplary acids include inorganic acids, such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulfuric acid, phosphoric acid; and organic acids such as formic acid, acetic acid, propanoic acid, hydroxyacetic acid, lactic acid, pyruvic acid, glycolic acid, maleic acid, malonic acid, oxalic acid, benzenesulfonic acid, toluenesulfonic acid, methanesulfonic acid, trifluoroacetic acid, fumaric acid, succinic acid, malic acid, tartaric acid, citric acid, salicylic acid, p-aminosalicylic acid, pamoic acid, benzoic acid, ascorbic acid and the like. Exemplary base addition salt forms are the sodium, potassium, calcium salts, and salts with pharmaceutically acceptable amines such as, for example, ammonia, alkylamines, benzathine, and amino acids, such as, e.g. arginine and lysine. The term addition salt as used herein also comprises solvates which the compounds and salts thereof are able to form, such as, for example, hydrates, alcoholates and the like.
For clinical use, the compounds of the invention are formulated into pharmaceutical formulations for oral, rectal, parenteral or other mode of administration. Pharmaceutical formulations are usually prepared by mixing the active substance, or a pharmaceutically acceptable salt thereof, with conventional pharmaceutical excipients. Examples of excipients are water, gelatin, gum arabicum, lactose, microcrystalline cellulose, starch, sodium starch glycolate, calcium hydrogen phosphate, magnesium stearate, talcum, colloidal silicon dioxide, and the like. Such formulations may also contain other pharmacologically active agents, and conventional additives, such as stabilizers, wetting agents, emulsifiers, flavouring agents, buffers, and the like. The formulations can be further prepared by known methods such as granulation, compression, microencapsulation, spray coating, etc. The formulations may be prepared by conventional methods in the dosage form of tablets, capsules, granules, powders, syrups, suspensions, suppositories or injections. Liquid formulations may be prepared by dissolving or suspending the
active substance in water or other suitable vehicles. Tablets and granules may be coated in a conventional manner.
In a further aspect the invention relates to methods of making compounds of any of the formulae herein comprising reacting any one or more of the compounds of the formulae delineated herein, including any processes delineated herein. The compounds of the formula (I) above may be prepared by, or in analogy with, conventional methods. The processes described above may be carried out to give a compound of the invention in the form of a free base or as an acid addition salt. A pharmaceutically acceptable acid addition salt may be obtained by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. Examples of addition salt forming acids are mentioned above.
The compounds of formula (I) may possess one or more chiral carbon atoms, and they may therefore be obtained in the form of optical isomers, e.g. as a pure enantiomer, or as a mixture of enantiomers (racemate) or as a mixture containing diastereomers. The separation of mixtures of optical isomers to obtain pure enantiomers is well known in the art and may, for example, be achieved by fractional crystallization of salts with optically active (chiral) acids or by chromatographic separation on chiral columns.
The necessary starting materials for preparing the compounds of formula (I) are either known or may be prepared in analogy with the preparation of known compounds.
The dose level and frequency of dosage of the specific compound will vary depending on a variety of factors including the potency of the specific compound employed, the metabolic stability and length of action of that compound, the patient's age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the condition to be treated, and the patient undergoing therapy. The daily dosage may, for example, range from about 0.001 mg to about 100 mg per kilo of body weight, administered singly or multiply in doses, e.g. from about 0.01 mg to about 25 mg each. Normally, such a dosage is given orally but parenteral administration may also be chosen. The invention will now be further illustrated by the following non-limiting Examples.
COMPARATIVE EXAMPLE 1 - 3-f3,4-dimethoxyphenyl)-l-methyl-lH-pyrrole-2,5- dione
3,4-dimethoxyaniline (7.66g, 50.0 mmol) was suspended in water/cone. HCl (2:3), (25 mL) with gentle heating. The reaction vessel was coooled (ice-bath) and some additional ice added to the reaction mixture. NaNO2 in water (13 mL) was added dropwise to the thick suspension. The mixture was stirred at 0-5 0C for 20 min, a dark brown foam was formed, which was removed by filtration. The filtrate was poured into an ice-cold solution of N-methylmaleimide (8.08g, 72.7 mmol) in acetone (40 mL). Solid NaOAc was added to the mixture to adjust the pH from 2 to 3. CuCl2.2H2O (1.31g, 7.7 mmol) was added with continous stirring and the temperature maintained at 0-5 0C for 30 min. The temperature was then increased to 35 0C and stirring continued over night for 20 hours. The acetone was evaporated and the remaining dark viscous oil was extracted with toluene (4x120 mL). The organic layers were combined, dried and concentrated. The residue was partly dissolved in i-PrOH (30 mL) and 2,6-dimethylpyridine was added. The mixture was heated to 50 0C and after 20 min a brown precipitation was noticed. The mixture was stirred for 2.5 h, water (20 mL) was added, and the mixture was cooled in a fridge. The mixture was then filtered and the collected solid washed with i-PrOH and then ether to give the title compound 2.98 g, 24% as a gold-brown solid. HPLC purity 95%, IH NMR (400 MHz, CHLOROFORM-D) δ ppm 3.04 (s, 3 H) 3.92 (s, 6 H) 6.58 (s, 1 H) 6.90 (d, J=8.53 Hz, 1 H) 7.48 (d, 7=2.01 Hz, 1 H) 7.60 (dd, J=8.53, 2.01 Hz, 1 H).
COMPARATIVE EXAMPLE 2 - (3aS*,7aR*)-7a-(3,4-dimethoxyphenyl)-2- methyltetrahvdro-lH-isoindole-l,3,5(2H,4H)-trione
2-(Trimethylsilyloxy)-l,3-butadiene and 3-(3,4-dimethoxyphenyl)-l-methyl-lH-pyrrole- 2,5-dione, prepared in comparative example 1, (6.947 g, 42.7 mmol) were dissolved in dry toluene (200 mL) and stirred at reflux for 64 h. The solvent was evaporated and the residue was dissolved in DCM (200 mL). Concentrated HCl was added dropwise with stirring over 25 min. The mixture was diluted with DCM and extracted with sat. aq. NaHCO3. The layers were separated and the aqueous layer was extracted once with DCM. The organic layers were combined, dried and concentrated to give 9.87 g of a yellow solid of 75% purity. Purification by flash chromatography (1 % MeOH in DCM) yielded 4.28 g (40%) of a yellow solid. HPLC purity 95%, IH NMR (400 MHz, CHLOROFORM-D) δ ppm 1.98 - 2.09 (m, 1 H) 2.30 - 2.44 (m, 3 H) 2.55 - 2.63 (m, 1 H) 2.83 (dd, 7=16.82, 7.78 Hz, 1 H) 2.93 - 3.00 (m, 1 H) 3.06 (s, 3 H) 3.53 - 3.57 (m, 1 H) 3.86 (s, 3 H) 3.88 (s, 3 H) 6.84 (d, J=8.53 Hz, 1 H) 6.88 - 6.92 (m, 1 H). MS (ESI+) for C17H19NO5 m/z 318 (M+H)+.
COMPARATIVE EXAMPLE 3 - 7a'-(3,4-dimethoxyphenyl)-2'- methyltetrahvdrospirori,3-dioxolane-2,5'-isoindolel-r,3'(2'H,4'H)-dione E05760001
Glycol (570 μL, 10.2 mmol) and benzenesulfonic acid (25 mg, 0.17 mmol) were added to a solution of (3aS ,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyltetrahydro-lH-isoindole- l,3,5(2H,4H)-trione, prepared in comparative example 2. The solution was refluxed at 115 0C using a Dean-Stark trap for 3 hours. The reaction mixture was allowed to cool and was extracted with sat. aq. NaHCO3 and brine. The organic layer was dried and concentrated to
give 320 mg of the title compound as a yellow solid. HPLC purity 86%, MS (ESI+) for C19H23NO6 m/z 362 (M+H)+.
COMPARATIVE EXAMPLE 4 - (3aS*,7aR*)-7a-(3,4-dimethoxyphenyl)-2- methyloctahydrospirori,3-dioxolane-2,5-isoindole1
7a'-(3,4-dimethoxyphenyl)-2'-methyltetrahydrospiro[l,3-dioxolane-2,5'-isoindole]- l',3'(2'H,4'H)-dione, prepared in comparative example 3, (3.41 g, 9.44 mmol) in THF (10 mL) was added by syringe to a cold suspension Of LiAlH4 (1.82 g, 47.9 mmol) in THF (60 mL). The mixture was heated to 65 0C and stirred for 2 hours. The vessel was cooled in an ice-bath and the reaction was quenched with water (6.39 mL). The resulting suspension was diluted with ether and filtered through celite which was rinsed several times with ether. The solvent was evaporated and the remaining residue was partitioned between DCM and IM aq. NaOH. Drying and concentration of the organic layer gave 2.68g (85%) of the title compound. HPLC purity 98%, MS (ESI+) for C19H27NO4 m/z 334 (M+H)+.
COMPARATIVE EXAMPLE 5 - (3aS*,7aR*)-7a-(3,4-dimethoxyphenyl)-2- methyloctahydro-5H-isoindol-5-one
To a solution of (3aS ,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydrospiro[l,3- dioxolane-2,5-isoindole], prepared in comparative example 4, (2.68 g, 8.04 mmol) in THF (40 mL), IM aq. HCl was added. The solution was stirred for 1.5 hours at 65 0C. The reaction mixture was diluted with ether then extracted with IM aq. NaOH. The layers were separated and the water phase was extracted once more with ether. The organic layers were combined, dried and concentrated to give 2.10 g (90%) of the title compound. HPLC purity 98%, IH NMR (500 MHz, CHLOROFORM-D) δ ppm 2.08 - 2.14 (m, 1 H) 2.14 - 2.20 (m,
1 H) 2.30 - 2.37 (m, 1 H) 2.33 (s, 3 H) 2.41 - 2.48 (m, 1 H) 2.55 (dd, 7=14.89, 7.32 Hz, 1 H) 2.59 (dd, J=9.28, 4.03 Hz, 1 H) 2.63 (dd, 7=15.01, 6.71 Hz, 1 H) 2.68 (dd, 7=7.69 Hz, 1 H) 2.71 (d, 7=9.16 Hz, 1 H) 2.93 (ddd, 7=14.01, 7.29, 4.21 Hz, 1 H) 3.04 (d, 7=9.16 Hz, 1 H) 3.87 (s, 3 H) 3.88 (s, 3 H) 6.79 - 6.83 (m, 3 H). MS (ESI+) for C17H23NO3 m/z 290 (M+H)+. The relative stereochemistry of this structure was further confirmed by NOE experiment.
COMPARATIVE EXAMPLE 6 - (3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2- methyloctahydro-lH-isoindol-5-amine
(3aS*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-5H-isoindol-5-one, prepared in comparative example, 5 (100 mg, 0.31 mmol) was aliquoted into 6 reaction vials and MeOH (5 ml) which had been saturated with ammonia gas was added to each vial. Sodium cyanoborohydride (35 mg, 0.56 mmol) was added to each vial and the mixtures were irradiated in a Smith microwave apparatus at 12O0C for 400 seconds. HPLC analysis showed consumption of starting material and the presence of the expected products (1:1 cis/trans) in all the vials. The mixtures were combined and evaporated and the residues partitioned between 0.5N NaOH and chloroform. Evaporation of the organic phase gave a light yellow liquid which was purified by flash-chromatography over silica using chloroform saturated with ammonia gas as the eluent. This gave (3aS*,5R*,7aR*)-7a-(3,4- dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-amine 0.172 g (30%) as a colorless oil. HPLC purity 99% MS (electro spray; [M+H]+) m/z: 291.1. IH NMR (400 MHz, CHLOROFORM-D) δ ppm 0.90 - 1.03 (m, 1 H) 1.07 - 1.34 (m, 2 H) 1.35 - 1.47 (m, 1 H) 1.55 - 1.65 (m, 1 H) 1.80 - 1.89 (m, 1 H) 1.95 - 2.10 (m, 2 H) 2.38 (s, 3 H) 2.62 (d, 7=9.03 Hz, 1 H) 2.73 - 2.81 (m, 7=9.03, 9.03 Hz, 1 H) 2.83 - 3.02 (m, 4 H) 3.84 (s, 3 H) 3.85 (s, 3 H) 6.76 - 6.83 (m, 2 H) 6.85 - 6.89 (m, 1 H).
EXAMPLE 7 - N-rf3aS*,5R*,7aR*)-7a-f3,4-dimethoxyphenyl)-2-methyloctahvdro-lH- isoindol-5-vH -4-iodobenzamide
A solution of (3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH- isoindol-5-amine, prepared in comparative example 6, (8.6 mg, 0.03 mmol) in THF (1.0 ml). Was treated with 4-iodobenzoyl chloride (0.04 mmol) and triethylamine (14 ul, 0.1 mmol). The mixture was stirred overnight then 2 drops of IN NaOH were added. The solvent was evaporated and the residue purified by preparative HPLC using acetonitrile- water 20-50 containing 0.1% TFA.
The fractions were pooled and the mixture was evaporated, dissolved in chloroform, then washed with IN NaOH. The organic phase was evaporated to give the title compound. Yield 6.0 mg (38%). White solid. HPLC purity 99%, MS (electro spray; [M+H]+) m/z: 521.2. HRMS for C24H29IN2O3: Calcd, 520.1223; found 520.1219.
EXAMPLE 8 - N-r(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahvdro-lH- isoindol-5-vH-3,4-dimethoxybenzamide trifluoroacetate
Procedure: as for example 7 Starting material: 3,4 dimethoxybenzoyl chloride.
Purified by reversed phase HPLC using acetonitrile-water 20-50 containing 0.1% TFA then evaporated to give the title compound. Yield 5.8 mg (34%). White solid. HPLC purity 99%, MS (electrospray; [M+H]+) m/z: 455.6. HRMS for C26H34N2O5: Calcd, 454.2468; found 454.2483.
EXAMPLE 9 - 4-chloro-N-rf3aS*,5R*,7aR*)-7a-f3,4-dimethoxyphenyl)-2- methyloctahvdro-lH-isoindol-5-vHbenzamide
Procedure: as for example 7
Starting material: 4-chlorobenzoyl chloride.
Yield 8.3 mg (64%). White solid. HPLC purity 99%, MS (electrospray; [M+H]+) m/z:
429.0. HRMS for C24H29ClN2O3: Calcd, 428.1867; found 428.1882.
EXAMPLE 10 - N-r(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahvdro-lH- isoindol-5-yl1-4-fluorobenzamide
Procedure: as for example 7
Starting material: 4-fluorobenzoyl chloride.
Yield 2.7 mg (22%). White solid. HPLC purity 99%, MS (electro spray; [M+H]+) m/z: 413.5. HRMS for C24H29FN2O3: Calculated 412.2162, found 412.2175.
EXAMPLE 11 - 4-bromo-N-r(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2- methyloctahvdro-lH-isoindol-5-ylibenzamide
Procedure: as for example 7 Starting material: 4-bromobenzoyl chloride.
Yield 3.8 mg (27%). White solid. HPLC purity 99%, MS (electro spray; [M+H]+) m/z: 474.4. HRMS for C24H29BrN2O3: Calcd, 472.1362; found 472.1366.
EXAMPLE 12 - N-r(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahvdro-lH- isoindol-5-yl1-3-fluoro-4-(trifluoromethyl)benzamide
Procedure: as for example 7 Starting material: 3-fluoro-4-(trifluoromethyl)benzoyl chloride.
Yield 7.3 mg (51%). White solid. HPLC purity 99%, MS (electro spray; [M+H]+) m/z: 481.5. HRMS for C25H28F4N2O3: Calcd, 480.2036; found 480.2051.
EXAMPLE 13 - 4-bromo-N-r(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2- methyloctahydro-lH-isoindol-5-yl1-3-methylbenzamide
Procedure: as for example 7
Starting material: 4-bromo-3-methyl benzoyl chloride.
Yield 5.4 mg (37%). White solid. HPLC purity 99%, MS (electro spray; [M+H]+) m/z:
489.4. HRMS for C25H31BrN2O3: Calcd, 486.1518; found 486.1506.
EXAMPLE 14 - N-r(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahvdro-lH- isoindol-5-yl1-4-fluoro-3-(trifluoromethyl)benzamide
Procedure: as for example 7
Starting material: 4-fluoro-3-(trifluoromethyl)benzoyl chloride.
Yield 6.8 mg (47%). White solid. HPLC purity 99%, MS (electro spray; [M+H]+) m/z:
481.5. HRMS for C25H28F4N2O3: Calcd, 480.2036; found 480.2027.
EXAMPLE 15 - N-rf3aS*,5R*,7aR*)-7a-f3,4-dimethoxyphenyl)-2-methyloctahvdro-lH- isoindol-5-vH-4-(trifluoromethyl)benzamide
Procedure: as for example 7
Starting material: 4-(trifluoromethyl)benzoyl chloride.
Yield 4.0 mg (29%). White solid. HPLC purity 99%, MS (electro spray; [M+H]+) m/z:
481.5. HRMS for C25H29F3N2O3: Calcd, 462.2130; found 462.2148.
EXAMPLE 16 - N-r(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahvdro-lH- isoindol-5-yl1-2,2-difluoro-l,3-benzodioxole-5-carboxamide
Starting material: 2,2-Difluoro-l,3-benzodioxole-5-carbonyl chloride.
Yield 4.0 mg (29%). White solid. HPLC purity 99%, MS (electro spray; [M+H]+) m/z:
475.5. HRMS for C25H28F2N2O5: Calcd, 474.1966,found 474.1985.
EXAMPLE 17 - N-(3-chloro-4-fluorophenyl)-N'-IY3aS*,5R*,7aR*)-7a-(3,4- dimethoxyphenyl)-2-methyloctahvdro-lH-isoindol-5-yl1urea trifluoroacetate
A solution of (3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH- isoindol-5-amine, prepared in comparative example 6, (8.6 mg, 0.03 mmol) in THF (1.0 ml) was treated with 3-chloro-4-fluorophenyl isocyanate (0.04 mmol). The mixture was stirred overnight then 2 drops of IN NaOH were added. The solvent was evaporated and the residue purified by preparative HPLC using acetonitrile-water 20-50 containing 0.1% TFA.
The fractions were pooled and the mixture was evaporated to give the title compound.
Yield 3.9 mg (23%). Colorless liquid. HPLC purity 99%, MS (electro spray; [M+H]+) m/z: 462.2. HRMS for C24H29ClFN3O3: Calcd, 461.1882, found 461.1885.
Example 18 - N44-chloro-3-(trifluoromethyl)phenyll-N'4(3aS*,5R*,7aR*)-7a-(3,4- dimethoxyphenvD^-methyloctahydro-lH-isoindol-S-yliurea trifluoroacetate
Procedure: as for example 17
Starting material: 4-chloro-3-(trifluoromethyl)phenyl isocyanate.
Yield 11.8 mg (63%). Light brown liquid. HPLC purity 95%, MS (electro spray; [M+H]+) m/z: 512.2. HRMS for C25H29ClF3N3O3: Calcd, 511.1850, found 511.1869.
EXAMPLE 19 - N-f3,5-difluorophenyl)-N'-rf3aS*,5R*,7aR*)-7a-f3,4-dimethoxyphenyl)- 2-methyloctahydro- lH-isoindol-5-vHurea trifluoroacetate
Procedure: as for example 17
Starting material: 3,5-difluorophenyl isocyanate.
Yield 8.3 mg (49%). Colorless liquid. HPLC purity 99%, MS (electro spray; [M+H]+) m/z:
446.2. HRMS for C24H29F2N3O3: Calcd, 445.2177, found 445.2189.
EXAMPLE 20 - N-r(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahvdro-lH- isoindol-5-yl1-N'-(2,3,4-trifluorophenyl)urea trifluoroacetate
Procedure: as for example 17
Starting material: 2,3,4-trifluorophenyl isocyanate.
Yield 9.5 mg (55%). Colorless liquid. HPLC purity 90%, MS (electro spray; [M+H]+) m/z:
464.2. HRMS for C24H28F3N3O3: Calcd, 463.2083, found 463.2077.
EXAMPLE 21 - N-r(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahvdro-lH- isoindol-5-yl1-N'-(3-fluorophenyl)urea trifluoroacetate
Procedure: as for example 17
Starting material: 3-fluorophenyl isocyanate.
Purified by reversed phase HPLC using ace tonitrile- water 20-50 containing 0.1% TFA.
The fractions were pooled and the mixture was evaporated. Isolated as the TFA-salt. Yield
5.6 mg (34%). Colorless liquid. HPLC purity 99%, MS (electro spray; [M+H]+) m/z: 428.2.
HRMS for C24H30FN3O3: Calcd, 427.2271, found 427.2267.
EXAMPLE 22 - N-(3-chlorophenyl)-N'-r(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2- methyloctahvdro-lH-isoindol-5-yliurea trifluoroacetate
Procedure: as for example 17
Starting material: 3-chlorophenyl isocyanate.
Yield 6.4 mg (38%). Colorless liquid. HPLC purity 99%, MS (electro spray; [M+H]+) m/z:
444.2. HRMS for C24H30ClN3O3: Calcd, 443.1976, found 443.1979.
EXAMPLE 23 - N-r(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahvdro-lH- isoindol-5-yliisonicotinamide 1-oxide trifluoroacetate
4-carboxypyridine-N-oxide (25 mg, 0.18 mmol), hydroxybenzotriazole (25 mg, 0.185 mmol), l-[3-(dimethylaminopropyl)]-3-ethylcarbodiimide hydrochloride (35 mg, 0.185 mmol and triethylamine (35 mg, 0.35 mmol) were mixed in DMF (2 ml) followed by addition of (3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol- 5-amine, prepared in comparative example 6, (35 mg, 0.12 mmol). The mixture was stirred for 2 hours then diluted with ether and washed twice with water. The aqueous layer was evaporated and the crude product was purified by reversed phase HPLC using acetonitrile-water 05-20 containing 0.1% TFA. To give the title compound. Yield 16.6 mg (26%). Colorless oil. HPLC purity 99%, MS (electronspray; [M+H]+) m/z: 412.2. HRMS for C23H29N3O4: Calcd, 411.2164, found 411.2158.
EXAMPLE 24 - N-(3,4-difluorophenyl)-N'-r(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)- 2-methyloctahvdro-lH-isoindol-5-vl1urea
3,4-difluorophenylisocyanate (22 mg, 0.14 mmol) was added to a solution of (3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-amine, prepared in comparative example 6, (35 mg, 0.12 mmol) in DCM (2 mL). The mixture was stirred over night at room temperature. The solvent was evaporated and the crude product purified by flash chromatography (CHCl3 sat. with NH3 (g)/iso-hexane, 60:40, 70:30,
100:0). To give the title compound (6 mg, 11%). HPLC purity 96%, IH NMR (500 MHz,
CHLOROFORM-D) δ ppm 1.01 (qd, 7=12.57, 12.24, 3.60 Hz, 1 H) 1.38 - 1.46 (m, 1 H) 1.76 - 1.84 (m, 1 H) 1.98 - 2.05 (m, 1 H) 2.03 - 2.10 (m, 1 H) 2.12 (td, 7=13.67, 3.30 Hz, 1 H) 2.40 (s, 3 H) 2.69 (d, 7=9.28 Hz, 1 H) 2.84 (t, 7=8.91 Hz, 1 H) 2.84 (d, 7=9.40 Hz, 1 H) 2.87 - 2.94 (m, 1 H) 3.06 (t, 7=8.91 Hz, 1 H) 3.85 (s, 3 H) 3.86 (s, 3 H) 3.87 - 3.97 (m, 1 H) 4.54 (d, 7=7.93 Hz, 1 H) 6.54 (s, 1 H) 6.81 (d, 7=8.42 Hz, 1 H) 6.84 (d, 7=2.20 Hz, 1 H) 6.86 - 6.90 (m, 1 H) 6.88 (dd, 7=8.30, 2.20 Hz, 1 H) 7.02 (dt, 7=9.89, 8.79 Hz, 1 H) 7.32 (ddd, 7=12.21, 7.08, 2.69 Hz, 1 H). MS (ESI+) for 446 m/z C24H29F2N3O3 (M+H)+.
EXAMPLE 25 - N-rf3aS*,5R*,7aR*)-7a-f3,4-dimethoxyphenyl)-2-methyloctahvdro-lH- isoindol-5-yl1-N'-r3-fluoro-5-(trifluoromethyl)phenyl1urea acetate
3-fluoro-5-(trifluoromethyl)phenylisocyanate (17 mg, 0.083 mmol) was added to a solution of (3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-amine, prepared in comparative example 6, (20 mg, 0.069 mmol) in DCM (1 mL). The reaction was stirred over night for 16 hours. Solvent was evaporated and the crude product was purified by preparative HPLC (ACE-column 30* 150mm, MeCN 30-65%, ammonium acetate buffer) to give the product (3 mg, 9%) as an off-white solid. HPLC purity 91%, IH NMR (400 MHz, CHLOROFORM-D) δ ppm 1.04 - 1.16 (m, 1 H) 1.55 (s, 1 H) 1.77 - 1.85 (m, 1 H) 1.95 - 2.07 (m, 2 H) 2.09 - 2.17 (m, 1 H) 2.68 (s, 3 H) 2.98 - 3.05 (m, 7=11.54 Hz, 1 H) 3.07 - 3.17 (m, 1 H) 3.29 (s, 2 H) 3.55 - 3.64 (m, 1 H) 3.84 (s, 3 H) 3.84 (s, 3 H) 3.87 - 3.88 (m, 1 H) 5.65 (br. s., 1 H) 6.76 - 6.78 (m, 1 H) 6.78 - 6.81 (m, 2 H) 6.84 - 6.88 (m, 1 H) 7.40 - 7.43 (m, 1 H) 7.46 - 7.54 (m, 1 H) 8.38 (s, 1 H). MS (ESI+) for C25H29F4N3O3 m/z 496 (M+H)+. HRMS CaIc: 495.2145 ; Found: 495.2144
EXAMPLE 26 - N-rf3aS*,5R*,7aR*)-7a-f3,4-dimethoxyphenyl)-2-methyloctahvdro-lH- isoindol-5-vH-N'-r2-fluoro-3-(trifluoromethyl)phenyriurea acetate
Procedure: as for example 25
Starting material: 2-fluoro-3-(trifluoromethyl)phenylisocyanate
Yield: 9 mg, 18%.
HPLC purity 90%, IH NMR (400 MHz, CHLOROFORM-D) δ ppm 1.13 (s, 1 H) 1.45 -
1.55 (m, 1 H) 1.80 - 1.88 (m, 1 H) 1.97 - 2.08 (m, 2 H) 2.13 - 2.21 (m, 1 H) 2.64 (s, 3 H)
3.08 (s, 2 H) 3.15 - 3.21 (m, 1 H) 3.22 - 3.30 (m, 1 H) 3.35 - 3.43 (m, 1 H) 3.84 (s, 6 H)
3.89 (s, 1 H) 5.60 - 5.65 (m, 1 H) 6.79 (d, J=8.28 Hz, 1 H) 6.81 - 6.82 (m, 1 H) 6.83 - 6.87
(m, 1 H) 7.10 - 7.16 (m, 2 H) 7.45 (s, 1 H) 8.30 - 8.40 (m, 1 H). MS (ESI+) for
C25H29F4N3O3 m/z 496 (M+H)+. HRMS CaIc: 495.2145 ; Found: 495.140
EXAMPLE 27 - N-f2,5-difluorophenyl)-N'-rf3aS*,5R*,7aR*)-7a-f3,4-dimethoxyphenyl)- 2-methyloctahvdro-lH-isoindol-5-yl1urea
Procedure: as for example 25
Starting material: 2,5-difluorophenylisocyanate
The product was purified by preparative HPLC then this material was extracted twice with
IM aq. NaOH and DCM to get rid of acetic acid. The organic layers were combined, dried and concentrated. This yielded 17 mg, 27%. HPLC purity 99%, IH NMR (400 MHz,
CHLOROFORM-D) δ ppm 0.99 - 1.11 (m, 1 H) 1.43 - 1.52 (m, 1 H) 1.79 - 1.86 (m, 1 H)
2.00 - 2.19 (m, 3 H) 2.40 (s, 3 H) 2.69 (d, J=9.29 Hz, 1 H) 2.84 (t, 7=8.91 Hz, 3 H) 3.07 (t,
J=8.66 Hz, 1 H) 3.85 (s, 3 H) 3.85 (s, 3 H) 3.89 - 3.99 (m, 1 H) 4.64 (d, J=7.53 Hz, 1 H)
6.53 - 6.62 (m, 2 H) 6.80 (d, J=8.53 Hz, 1 H) 6.82 (d, 7=2.01 Hz, 1 H) 6.85 - 6.89 (m, 1 H) 6.89 - 6.99 (m, 1 H) 7.90 - 8.00 (m, 1 H). MS (ESI+) for C24H29F2N3O3 m/z 446 (M+H)+.
EXAMPLE 28 - 3,4-dichloro-N-rf3aS*,5R*,7aR*)-7a-f3,4-dimethoxyphenyl)-2- methyloctahvdro-lH-isoindol-5-vHbenzamide
NEt3 (31 μL, 0.22 mmol) and 3,4-dichlorobenzoyl chloride (28 mg, 0.13 mmol) were added to a solution of (3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH- isoindol-5-amine, prepared in comparative example 6, (32 mg, 0.11 mmol) in DCM (1,5 mL). The mixture was stirred at rt. for 1.5 hours. Purification as in example 27, afforded 9 mg, 18%. HPLC purity 90%, IH NMR (270 MHz, CHLOROFORM-D) δ ppm 1.08 - 1.21 (m, 1 H) 1.52 - 1.66 (m, 1 H) 1.83 - 1.94 (m, 1 H) 2.01 - 2.11 (m, 1 H) 2.11 - 2.21 (m, 2 H) 2.42 (s, 3 H) 2.70 (d, J=9.15 Hz, 1 H) 2.83 - 3.02 (m, 3 H) 3.12 (t, J=8.04 Hz, 1 H) 3.86 (s, 3 H) 3.88 (s, 3 H) 4.16 - 4.33 (m, 1 H) 5.76 (d, J=7.67 Hz, 1 H) 6.82 (d, J=8.41 Hz, 1 H) 6.85 (d, J=I.98 Hz, 1 H) 6.88 - 6.94 (m, 1 H) 7.42 - 7.54 (m, 2 H) 7.76 (d, J=I.73 Hz, 1 H). MS (ESI+) for C24H28Cl2N2O3 m/z 463 (Monoiso. Mass+H)+. HRMS CaIc: 462.1477 ; Found: 462.1484
EXAMPLE 29 - N-r(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahvdro-lH- isoindol-5-vH-N'-(3A5-trifluorophenyl)urea
Triphosgene (17 mg, 0.058 mmol) in DCM (1 mL) was, added dropwise under N2 , to a solution of (3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5- amine, prepared in comparative example 6, (42 mg, 0.14 mmol) and dry NEt3 (40 μL, 0.28 mmol) in DCM (2 mL). The solution was stirred at rt. for 3 hours, then 3,4,5-
trifluoroaniline (21 mg, 0.14 mmol) was added and stirring continued over night. Purification and work-up as for example 27, afforded the product as the free base (8 mg, 12%). HPLC purity 100%, IH NMR (400 MHz, CHLOROFORM-D) δ ppm 0.91 - 1.04 (m, 1 H) 1.34 - 1.44 (m, 1 H) 1.77 - 1.81 (m, 1 H) 1.96 - 2.15 (m, 3 H) 2.39 (s, 3 H) 2.67 (d, J=9.29 Hz, 1 H) 2.82 (dd, 7=9.16, 7.40 Hz, 3 H) 3.03 (t, J=8.53 Hz, 1 H) 3.83 (s, 3 H) 3.84 (s, 3 H) 3.87 - 3.95 (m, 1 H) 4.66 (d, J=7.78 Hz, 1 H) 6.78 - 6.84 (m, 2 H) 6.85 - 6.89 (m, 1 H) 6.99 - 7.06 (m, 2 H). MS (ESI+) for C24H28F3N3O3 m/z 464 (M+H)+. HRMS CaIc: 463.2083 ; Found: 463.2088
COMPARATIVE EXAMPLE 30 - (3aS*,5S*,7aR*)-7a-(3,4-dimethoxyphenyl)-2- methyloctahvdro-lH-isoindol-5-amine
(3aS ,7aR )-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-5H-isoindol-5-one, prepared in comparative example 5, (132 mg, 0.45 mmol) was dissolved in dry methanol (25 mL). Ammonium acetate (3 eq) was added and the mixture was stirred at 65 0C for 30 minutes, whereafter NaCNBH3 (1.2 eq) was added. The reaction was stirred an additional 15 min with continous stirring. The solvent was evaporated and the residue was partitioned between IM aq. NaOH (20 mL) and DCM (20 mL). The aq. layer was extracted once more with DCM and the organic layers were combined, dried and evaporated to give the crude product which was purified by flash-chromatography over silica (CHCl3 sat. with NH3 (g)/iso-hexane, 60:40) to give the title compound (11 mg, 8%). HPLC purity 90%, IH NMR (500 MHz, CHLOROFORM-D) δ ppm 1.30 - 1.39 (m, 1 H) 1.40 (dt, 7=13.18, 10.86, 10.62 Hz, 1 H) 1.66 - 1.73 (m, 1 H) 1.70 - 1.77 (m, 1 H) 1.85 - 1.93 (m, 7=13.08, 5.72, 4.09, 1.28 Hz, 1 H) 1.98 - 2.06 (m, 1 H) 2.41 (s, 3 H) 2.50 (dd, 7=9.46, 2.38 Hz, 1 H) 2.51 - 2.58 (m, 1 H) 2.80 - 2.88 (m, 1 H) 2.91 (dd, 7=9.40, 6.59 Hz, 1 H) 2.91 - 2.95 (m, 7=9.64 Hz, 1 H) 3.04 (d, 7=9.64 Hz, 1 H) 3.86 (s, 3 H) 3.89 (s, 3 H) 6.81 (d, 7=8.42 Hz, 1 H) 6.91 (d, 7=2.20 Hz, 1 H) 6.94 (dd, 7=8.30, 2.32 Hz, 1 H). MS (ESI+) for C17H26N2O2
m/z 291 (M+H)+. The relative stereochemistry of this structure was further confirmed by NOE experiment.
EXAMPLE 31 - N-rf3aS*,5S*,7aR*)-7a-f3,4-dimethoxyphenyl)-2-methyloctahvdro-lH- isoindol-5-vH-N'-r2-fluoro-3-(trifluoromethyl)phenyl"lurea acetate
2-fluoro-3-(trifluoromethyl)phenylisocyanate (16 mg, 0.079 mmol) was added to a solution of (3aS*,5S*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-amine, prepared in comparative example 30, (20 mg, 0.069 mmol) in DCM (1 mL). The reaction was stirred over night for 16 hours. Solvent was evaporated and the crude product was purified by preparative HPLC (ACE-column 30 x 150mm, MeCN 30-65%, ammonium acetate buffer) to give 19 mg, 60%. HPLC purity 95%, IH NMR (400 MHz, CHLOROFORM-D) δ ppm 1.39 - 1.49 (m, 1 H) 1.53 - 1.64 (m, J=12.55 Hz, 2 H) 1.90 - 2.07 (m, 2 H) 2.25 - 2.34 (m, 1 H) 2.68 (s, 3 H) 2.75 (d, J=I 1.04 Hz, 1 H) 3.00 (t, J=I 1.17 Hz, 1 H) 3.05 - 3.13 (m, 1 H) 3.71 (d, 7=11.04 Hz, 1 H) 3.87 (s, 6 H) 4.13 - 4.19 (m, 1 H) 4.41 - 4.48 (m, 1 H) 6.75 - 6.76 (m, 1 H) 6.83 - 6.86 (m, 2 H) 7.06 - 7.17 (m, 2 H) 7.81 - 7.87 (m, 1 H) 8.51 - 8.58 (m, 1 H) 8.60 - 8.68 (m, 1 H). HRMS CaIc: 495.2145 ; Found: 495.2143
EXAMPLE 32 - 3,4-dichloro-N-r(3aS*,5S*,7aR*)-7a-(3,4-dimethoxyphenyl)-2- methyloctahvdro-lH-isoindol-5-vHbenzamide
Procedure: as for example 28.
Starting material: (3aS*,5S*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH- isoindol-5-amine prepared in comparative example 30, (25 mg ; 0.086 mmol)
Yield 8 mg. HPLC purity 96%, IH NMR (270 MHz, METHANOL-D4) δ ppm 1.42 - 1.64 (m, 3 H) 1.65 - 1.74 (m, 1 H) 1.94 - 2.05 (m, 2 H) 2.57 (s, 3 H) 2.95 - 3.11 (m, 2 H) 3.16 - 3.22 (m, 1 H) 3.61 - 3.67 (m, 2 H) 3.67 (s, 3 H) 3.72 (s, 3 H) 3.78 - 3.91 (m, 1 H) 6.79 - 6.84 (m, 1 H) 6.90 - 6.96 (m, 2 H) 7.48 (d, 7=8.41 Hz, 1 H) 7.58 - 7.65 (m, 1 H) 7.85 (d, J=I.98 Hz, 1 H). MS (ESI+) for C24H28Cl2N2O3 m/z 463 (Monoiso. Mass+H)+. HRMS CaIc: 462.1477 ; Found: 462.1471
EXAMPLE 33 - N-rf3aS*,5R*,7aR*)-7a-f3,4-dimethoxyphenyl)-2-methyloctahvdro-lH- isoindol-5-yl1-N'-r4-fluoro-3-(trifluoromethyl)phenyl1urea trifluoroacetate
A solution of (3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH- isoindol-5-amine, prepared in comparative example 6, (11.2 mg; 0.038 mmol) in THF (2.0 ml) was treated with the 4-fluoro-3-(trifluoromethyl)phenylisocyanate (1 eq) and the mixture was allowed to stand at RT overnight The solvent was evaporated and the residues purified by HPLC (YMC column - gradient 20-60 MeCN) to afford the title compound (10.9 mg) as a colourless solid. MS (ESI+) for C24H28Cl2N2O3 m/z 466 (Monoiso. Mass+H)+.
EXAMPLE 34 and EXAMPLE 35- N-r(3aS,5R,7aR)-7a-(3,4-dimethoxyphenyl)-2- methyloctahvdro-lH-isoindol-5-yl1-N'-r4-fluoro-3-(trifluoromethyl)phenyl1urea and N- r(3aR,5S,7aS)-7a-(3,4-dimethoxyphenyl)-2-methyloctahvdro-lH-isoindol-5-yll-N'-r4- fluoro-3-(trifluoromethyl)phenyl1urea
N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-yl]-N'- [4-fluoro-3-(trifluoromethyl)phenyl]urea trifluoroacetate, prepared in example 33, (10.0 mg) was resolved into separate enantiomers by chiral high-performance column chromatography.
Column: Chirobiotic V (250 x 6 mm), 5 microns Mobile Phase: MeOH / AcOH / Triethylamine (100 / 0.1 / 0.1) Flow Rate: 5 ml/min Run Time: 30 min Temp: 21 0C
The first eluted peak was collected and the solvent evaporated to give 1.1 mg of a colourless solid which was arbitrarily assigned as N-[(3aS,5R,7aR)-7a-(3,4- dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-yl]-N'-[4-fluoro-3- (trifluoromethyl)phenyl]urea, HRMS CaIc for C25H29F4N3O3: 495.2145, HRMS Found: 495.2125
The second eluted peak was collected and the solvent evaporated to give 3.3 mg of a colourless solid which was was arbitrarily assigned as N-[(3aR,5S,7aS)-7a-(3,4- dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-yl]-N'-[4-fluoro-3- (trifluoromethyl)phenyl]urea, HRMS CaIc for C25H29F4N3O3: 495.2145, HRMS Found: 495.2142
EXAMPLE 36 - N-rf3aS*,5R*,7aR*)-7a-f3,4-Dimethoxyphenyl)-2-methyloctahvdro-lH- isoindol-5-yl1-3-fluorobenzamide trifluoroacetate
3-fluorobenzoyl chloride (7 mg, 0.0461 mmol) was added a solution of (3aS*,5R*,7aR*)- 7a-(3,4-dimethoxyphenyl)-2-methyloctahydro- lH-isoindol-5-amine, prepared in comparative example 6, (13 mg, 0.0461 mmol) in DCM (1 ml) and triethylamine (8 μl, 0.0538 mmol). The mixture was stirred overnight then the solvent was evaporated. The residue was purified by preparative HPLC to yield 1.8 mg of the desired TFA-salt. Yield 7%, HPLC purity 98%, m/z 413 (M+H)+, HRMS for C24H29FN2O3: calcd: 412.2162, found: 412.2162.
EXAMPLE 37 - 3-Chloro-N-r(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2- methyloctahvdro-lH-isoindol-5-vHbenzamide trifluoroacetate
Procedure: as for example 36
Starting material: 3-chlorobenzoyl chloride
Yield 15%, HPLC purity 99%, m/z 429 (M+H)+, HRMS for C24H29ClN2O3: calcd:
428.1867, found: 428.1851.
EXAMPLE 38 - 3-Bromo-N-rf3aS*,5R*,7aR*)-7a-f3,4-dimethoxyphenyl)-2- methyloctahvdro-lH-isoindol-5-vHbenzamide trifluoroacetate
Procedure: as for example 36
Starting material: 3-bromobenzoyl chloride
Yield 17%, HPLC purity 99%, m/z 473 (M+H)+, HRMS for C24H29BrN2O3: calcd:
472.1362, found: 472.1362. IH NMR (270 MHz, METHANOL-D3) δ ppm 0.87 - 1.08 (m,
1 H) 1.32 - 1.49 (m, 1 H) 1.54 - 1.68 (m, 1 H) 1.79 - 1.93 (m, 1 H) 1.99 - 2.09 (m, 2 H)
2.39 (s, 3 H) 2.63 (d, 7=9.15 Hz, 1 H) 2.73 - 3.06 (m, 5 H) 3.85 (s, 3 H) 3.86 (s, 3 H) 6.73 -
6.96 (m, 3 H) 7.29 - 7.41 (m, 1 H) 7.64 - 7.70 (m, 1 H) 7.71 - 7.78 (m, 1 H) 7.93 - 7.98 (m,
I H).
EXAMPLE 39 - 3-rfDifluoromethyl)thiol-N-rf3aS*,5R*,7aR*)-7a-f3,4-dimethoxyphenyl)- 2-methyloctahydro- lH-isoindol-5-vHbenzamide trifluoroacetate
Procedure: as for example 36
Starting material: 3-difluoromethylthiobenzoyl chloride Yield 14%, HPLC purity 100%, m/z 477 (M+H)+, HRMS for C25H30F2N2O3S: calcd: 476.1945, found: 476.1942.
EXAMPLE 40 - 3-Cyano-N-r(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2- methyloctahvdro-lH-isoindol-5-vHbenzamide trifluoroacetate
Procedure: as for example 36
Starting material: 3-cyanobenzoyl chloride
Yield 12%, HPLC purity 100%, m/z 420 (M+H)+, HRMS for C25H29N3O3: calcd: 419.2209, found: 419.2202.
EXAMPLE 41 - 4-Cyano-N-r(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2- methyloctahvdro-lH-isoindol-5-vHbenzamide trifluoroacetate
Procedure: as for example 36
Starting material: 4-cyanobenzoyl chloride Yield 14%, HPLC purity 96%, m/z 420 (M+H)+, HRMS for C25H29N3O3: calcd: 419.2209, found: 419.2201, IH NMR (270 MHz, METHANOL-D3) δ ppm 0.87 - 1.08 (m, 1 H) 1.32
- 1.49 (m, 1 H) 1.54 - 1.68 (m, 1 H) 1.79 - 1.93 (m, 1 H) 1.99 - 2.09 (m, 2 H) 2.39 (s, 3 H)
2.63 (d, 7=9.15 Hz, 1 H) 2.73 - 3.06 (m, 5 H) 3.85 (s, 3 H) 3.86 (s, 3 H) 6.73 - 6.96 (m, 3
H) 7.74 - 7.96 (m, 4 H).
EXAMPLE 42 - N-rf3aS*,5R*,7aR*)-7a-f3,4-Dimethoxyphenyl)-2-methyloctahvdro-lH- isoindol-5-yl1-3,4-difluorobenzamide trifluoroacetate
Procedure: as for example 36
Starting material: 3,4-difluorobenzoyl chloride
Yield 11%, HPLC purity 97%, m/z 431 (M+H)+, HRMS for C24H28F2N2O3: calcd:
430.2068, found: 430.2087.
EXAMPLE 43 - N-rf3aS*,5R*,7aR*)-7a-f3,4-Dimethoxyphenyl)-2-methyloctahvdro-lH- isoindol-S-yli^-fluoro-S-CtrifluoromethvDbenzamide trifluoroacetate
Procedure: as for example 36
Starting material: 3-fluoro-5-(trifluoromethyl)benzoyl chloride Yield 10%, HPLC purity 100%, m/z 481 (M+H)+, HRMS for C25H28F4N2O3: calcd: 480.2036, found: 480.2040.
EXAMPLE 44 - N-rf3aS*,5R*,7aR*)-7a-f3,4-Dimethoxyphenyl)-2-methyloctahvdro-lH- isoindol-5-yl1-2-fluoro-4-(trifluoromethyl)benzamide trifluoroacetate
Procedure: as for example 36
Starting material: 2-fluoro-4-(trifluoromethyl)benzoyl chloride Yield 18%, HPLC purity 98%, m/z 481 (M+H)+, HRMS for C25H28F4N2O3: calcd: 480.2036, found: 480.2026, IH NMR (270 MHz, METHANOL-D3) δ ppm 0.87 - 1.08 (m, 1 H) 1.32 - 1.49 (m, 1 H) 1.54 - 1.68 (m, 1 H) 1.79 - 1.93 (m, 1 H) 1.99 - 2.09 (m, 2 H) 2.39 (s, 3 H) 2.63 (d, 7=9.15 Hz, 1 H) 2.73 - 3.06 (m, 5 H) 3.85 (s, 3 H) 3.86 (s, 3 H) 6.73 - 6.96 (m, 3 H) 7.49 - 7.81 (m, 3 H).
EXAMPLE 45 - N-rf3aS*,5R*,7aR*)-7a-f3,4-Dimethoxyphenyl)-2-methyloctahvdro-lH- isoindol-5-yl1-4-r(trifluoromethyl)thio1benzamide trifluoroacetate
Procedure: as for example 36
Starting material: 4-(trifluoromethylthio)benzoyl chloride
Yield 15%, HPLC purity 97%, m/z 495 (M+H)+, HRMS for C25H29F3N2O3S: calcd: 494.1851, found: 494.1857, IH NMR (270 MHz, METHANOL-D3) δ ppm 0.87 - 1.08 (m, 1 H) 1.32 - 1.49 (m, 1 H) 1.54 - 1.68 (m, 1 H) 1.79 - 1.93 (m, 1 H) 1.99 - 2.09 (m, 2 H) 2.39 (s, 3 H) 2.63 (d, 7=9.15 Hz, 1 H) 2.73 - 3.06 (m, 5 H) 3.85 (s, 3 H) 3.86 (s, 3 H) 6.73 - 6.96 (m, 3 H) 7.71 - 7.89 (m, 4 H).
EXAMPLE 46 - 3-Chloro-N-rf3aS*,5R*,7aR*)-7a-f3,4-dimethoxyphenyl)-2- methyloctahydro-lH-isoindol-S-yli^-fluorobenzamide trifluoroacetate
Procedure: as for example 36 Starting material: 3-chloro-2-fluorobenzoyl chloride
Yield 12%, HPLC purity 97%, m/z 447 (M+H)+, HRMS for C24H28ClFN2O3: calcd: 446.1772, found: 446.1768.
EXAMPLE 47 - N-rf3aS*,5R*,7aR*)-7a-f3,4-Dimethoxyphenyl)-2-methyloctahvdro-lH- isoindol-5-yl1-2,5-difluorobenzamide trifluoroacetate
Procedure: as for example 36 Starting material: 2,5-difluorobenzoyl chloride Yield 15%, HPLC purity 99%, m/z 431 (M+H)+, HRMS for C24H28F2N2O3: calcd: 430.2068, found: 430.2052
EXAMPLE 48 - N-rf3aS*,5R*,7aR*)-7a-f3,4-Dimethoxyphenyl)-2-methyloctahvdro-lH- isoindol-5-yl1-N'-(3,5-dimethylphenyl)urea trifluoroacetate
l-isocyanato-3,5-dimethylbenzene (7 mg, 0.0454 mmol) was added a solution of (3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-amine, prepared in comparative example 6, (12 mg, 0.0413 mmol) in DCM (1 ml). The mixture was stirred overnight and the solvent evaporated. The residue was purified by preparative HPLC to yield 3.0 mg of the desired TFA-salt. Yield 13%, HPLC purity 91%, m/z 438 (M+H)+, HRMS for C26H35N3O3: calcd: 437.2678, found: 437.2688.
EXAMPLE 49 - N-(2,5-Dichlorophenyl)-N'-r(3aS*,5R*,7aR*)-7a-(3,4- dimethoxyphenvD^-methyloctahydro-lH-isoindol-S-yliurea trifluoroacetate
Procedure: as for example 48 Starting material: 2,5-dichlorophenylisocyanate Yield 18%, HPLC purity 90%, m/z 478 (M+H)+, HRMS for C24H29Cl2N3O3: calcd: 477.1586, found: 477.1586.
EXAMPLE 50 - N-(2Λ-Dichlorophenyl)-N'-IY3aS*,5R*,7aR*)-7a-(3,4- dimethoxyphenvD-l-methyloctahydro-lH-isoindol-S-yliurea trifluoroacetate
Procedure: as for example 48 Starting material: 2,4-dichlorophenylisocyanate
Yield 38%, HPLC purity 98%, m/z 478 (M+H)+, HRMS for C24H29Cl2N3O3: calcd: 477.1586, found: 477.1588.
EXAMPLE 51 - N-r(3aS*.5R*.7aR*)-7a-f3,4-Dimethoxyphenyl)-2-methyloctahvdro-lH- isoindol-5-yl1-N'-(4-iodophenyl)urea trifluoroacetate
Yield 39%, HPLC purity 100%, m/z 536 (M+H)+, HRMS for C24H30IN3O3: calcd: 535.1332, found: 535.1313, IH NMR (400 MHz, DMSO-D6, 7O0C due to rotamers) δ ppm 0.93 - 1.14 (m, 1 H) 1.46 - 1.64 (m, 1 H) 1.68 - 1.84 (m, 1 H) 1.89 - 2.24 (m, 3 H) 2.91 (s, 3 H) 3.00 - 3.40 (m, 6 H) 3.78 (s, 3 H) 3.82 (s, 3 H) 6.95 - 7.05 (m, 3 H) 7.29 (dd, J=9.03, 2.44 Hz, 1 H) 7.48 (d, J=2.44 Hz, 1 H) 8.10 - 8.18 (m, J=8.91 Hz, 1 H).
EXAMPLE 52 and EXAMPLE 53 - N-r(3aS,5R,7aR)-7a-(3,4-dimethoxyphenyl)-2- methyloctahydro-lH-isoindol-5-yl1-3-fluoro-4-(trifluoromethyl)benzamide trifluoroacetate and N-rf3aR,5S,7aS)-7a-f3,4-dimethoxyphenyl)-2-methyloctahvdro-lH-isoindol-5-yl1-3- fluoro-4-(trifluoromethyl)benzamide trifluoroacetate
A sample of N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH- isoindol-5-yl]-3-fluoro-4-(trifluoromethyl)benzamide (17 mg), was prepared as in example 12, and was resolved by chiral HPLC in an analogous manner to the resolution carried out in examples 34 and 35.
The first eluted peak was collected and the solvent evaporated to give 1.2 mg of a colourless solid. The absolute stereochemistry was arbitrarily assigned as N-
[(3aS,5R,7aR)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-yl]-N'-[4- fluoro-3-(trifluoromethyl)phenyl]urea, IH NMR (500 MHz, DMSO-D6) δ ppm 1.2 (s, 1 H) 1.7 (m, 2 H) 1.9 (m, 1 H) 2.0 (s, 1 H) 2.2 (t, J=14.1 Hz, 1 H) 2.9 (m, 2 H) 2.9 (m, 2 H) 3.3 (s, 3 H) 3.6 (d, J=8.8 Hz, 1 H) 3.7 (m, 1 H) 3.8 (s, 3 H) 3.8 (d, 7=1.6 Hz, 3 H) 7.0 (s, 3 H) 7.9 (s, 3 H) 8.5 (s, 1 H).HRMS CaIc for C25H28F4N2O3: 480.2036, HRMS Found: 480.2023, optical rotation [α]D (+ 2 )
The second eluted peak was collected and the solvent evaporated to give 5.5 mg of a colourless solid. The absolute stereochemistry was arbitrarily assigned as N-[(3aR,5S,7aS)- 7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-yl]-N'-[4-fluoro-3-
(trifluoromethyl)phenyl]urea, HRMS CaIc for C25H28F4N2O3: 480.2036, HRMS Found: 408.2053, optical rotation [α]D (- 1.5)
EXAMPLE 54 - N44-Bromo-2-(trifluoromethyl)phenyll-N'4(3aS^5R^7aR*)-7a-(3,4- dimethoxyphenyl)-2-methyloctahvdro-lH-isoindol-5-yl"|urea trifluoroacetate
Procedure: as for example 48
Starting material: 4-bromo-2-(trifluoromethyl)phenylisocyanate Yield: 13%, HPLC purity 96%, m/z 556 (M+H)+, HRMS for C25H29BrF3N3O3: calcd: 555.1344, found: 555.1339.
EXAMPLE 55 - N-(3-Cvanophenyl)-N'-rf3aS*,5R*,7aR*)-7a-f3,4-dimethoxyphenyl)-2- methyloctahydro-lH-isoindol-5-vHurea trifluoroacetate
Procedure: as for example 48
Starting material: 3-cyanophenylisocyanate
Yield 22%, HPLC purity 93%, m/z 435 (M+H)+, HRMS for C25H30N4O3: calcd: 434.2318, found: 434.2302.
EXAMPLE 56 - N-rf3aS*.5R*.7aR*)-7a-f3,4-Dimethoxyphenyl)-2-methyloctahvdro-lH- isoindol-5-yl1-3-(trifluoromethyl)benzamide trifluoroacetate
3-(trifluoromethyl)benzoyl chloride (9 mg, 0.0454 mmol) was added a solution of (3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-amine, prepared in comparative example 6, (12 mg, 0.0413 mmol) in DCM (1 ml) and triethylamine (8 μl, 0.0538 mmol). The mixture was stirred overnight and the solvent evaporated. The product was purified by preparative HPLC to yield 7.1 mg of the title compound. Yield 30%, HPLC purity 93%, m/z 463 (M+H)+, HRMS for C25H29F3N2O3: calcd: 462.2130, found: 462.2121.
PREPARATION OF A PHARMACEUTICAL COMPOSITION
EXAMPLE 57: Preparation of tablets
Ingredients mg/tablet
1. Active compound of formula (I) 10.0
2. Cellulose, microcrystalline 57.0
3. Calcium hydrogen phosphate 15.0
4. Sodium starch glycolate 5.0
5. Silicon dioxide, colloidal 0.25
6. Magnesium stearate 0.75
The active ingredient 1 is mixed with ingredients 2, 3, 4 and 5 for about 10 minutes. The magnesium stearate is then added, and the resultant mixture is mixed for about 5 minutes and compressed into tablet form with or without film-coating.
BIOLOGICAL METHODS
The ability of a compound of the invention to bind or act at the MCHlR receptor can be determined using in vitro and in vivo assays known in the art.
Binding assay
The compounds according to the invention were evaluated for their binding to the human MCHlR receptor by the following method:
Materials and methods
Materials
Compounds: MCH peptide was purchased from Phoenix pharmaceuticals. (Phe13, [125I]Tyr19 Melanine-Concentrating Hormone (human, mouse, rat) ([125I]-MCH) was obtained from NEN life Science Products. Inc. Boston, MA. Wheat germ agglutinine SPA beads (RPNQ 0001) were obtained from Amersham-Pharmacia Biotech. All other reagents used are of highest purity from different resources available. Protein Kits, Micro BCA™ Protein Assay Reagent Kit (Cat No. 23235) were purchased from Piece, Rockford, IL, USA. Plastic wares: Cell culture flasks, dishes were from Decton Dickinson Labware, NJ, USA. Scintillation plate, white clear bottom were from Wallac, Finland.
Cells and culture conditions
CHO-Kl hMCHRI (Euroscreen, Brussels, Belgium, # ES-370-C) were cultivated in Nutrient mixture Ham's F- 12 with Glutamax I (Gibco-BRL #31765-027) supplemented with 10% heat-inactivated foetal calf serum (FCS, Gibco-BRL #10108-165) and 400 μg/ml geniticin (Gibco-BRL #1140-0359). The cells were sub-cultivated twice weekly with split ratio= 1:20-1:30. For membrane preparation the cells were cultured in 500 mm2 dishes and the cells were harvested when 90% confluent.
Membrane preparation
When the cells reached more than 90% confluence, dishes (500 cm2 ) were rinsed twice with 20 ml PBS (Ca2+ and Mg2+ free). Buffer A, which contains Tris.HCl (15), MgCl2.6H2O (2), EDTA (0.3), EGTA (1) in mM with pH 7.5, 25ml was added and cells were suspended using a window scraper. The cells were collected in 50 ml Falcon tube pre-cooled on ice and then centrifuged for 3 minutes at 150Og at 4 °C. The supernatant was discarded and the cells were suspended again with Buffer A. The cells were homogenized using a Polytron homogenizer at setting 4 for 4 times for 30 seconds with 1 minute pause between the cycles. The homogenized preparation was centrifuged at 40,00Og (18500 rpm with ss-34, No. 5 rotor in Sorvall centrifuge, RC5C, DuPont) for 25 minutes at 4 °C. The pellets were washed once with Buffer A and centrifuged again under the same conditions. The pellets were suspended with Buffer B, which contains Tris.HCl (7.5), MgCl2.6H2O (12.5), EDTA (0.3), EGTA (1), sucrose (25) in mM with pH 7.5, and gently homogenized for several times with a glass homogenizer. The membrane preparation was aliquoted into Eppendorf tubes, 1 ml/tube and frozen at -70 °C.
Membrane protein determination
The protein determination was done as described in the instruction provided with Pierce protein assay kit (Peirce Micro BCA Protein assay reagent kit, No 23235, Pierce, USA).
Receptor binding by SPA
The WGA beads were re-constituted with reaction buffer, which contains Tris (50), MgCl2 (5), EDTA (2.5) in mM with pH adjusted to 7.4, to 40 mg/ml as a stock suspension. To link the membrane with the bead, the beads and the membrane will be pre-incubated with for 30 minutes at room temperature with gentle shaking. The suspension of the beads was centrifuged at 3400 rpm for 2 minutes using centrifuge. The supernatant was discarded and the beads were re-suspended with binding buffer, HEPES (25mM), MgCl2 (5mM), CaCl2 (ImM), BSA (0.5%) with peptidase inhibitors (lμg/ml) Leupeptin, Aprotinin and pepstatin, pH 7.4. The radio labeled [125I]-MCH was diluted with cold MCH in ratio 1:3. In Kd determination, the concentrations of labeled peptide were 3 nM with 1:2 series dilution for
11 samples. The amount of the beads was 0.25 mg/well. The results were calculated using Excel program and the curves were drawn using a program GraphPad Prism.
For screening of the substances the amount of the beads used was 0.25 mg/well and the amount of the membrane protein was 4 μg/well. In all displacement experiments, 0.2 nM [ I]-MCH was used for total binding and 300 nM MCH used as non-specific binding. The total volume was 200 μl, which contained 50 μl [ I]-MCH, 100 μl substances and 50 μl beads. The plate was gently shaken for 30 minute and incubated overnight. The samples were counted using Microbeta counter (Wallac Trilux 1450 Micro beta counter, Wallac, Finland) for 2 minutes and the results were calculated by using the computer program Activity Base.
Results
The K1 value is calculated from IC50 using the Cheng Prushoff equation : K1 = IC50(l+[S]/Km) [Cheng, Y.C.; Prushoff, W.H. Biochem. Pharmacol. 1973, 22, 3099-3108].
The compounds of formula (I) exhibit the IC50 values for the MCHlR receptor in the range from 1 nM to 10 μM. Illustrative of the invention, the following Ki values have been determined in the assay (see Table 1):
Table 1 : Ki values determined in the assay.
Claims
1. A compound of the general formula (I)
or a pharmaceutically acceptable salt, hydrates, geometrical isomers, racemates, tautomers, optical isomers, N-oxides and prodrug forms thereof, wherein:
X is NH or a single bond; Ar is aryl, wherein the aryl may be substituted by one or more of C^-alkoxy;
R1 is Ci-6-alkyl;
R2 is H;
R3 is selected from aryl optionally substituted by one or more of halogen, cyano, halo-Ci-6- alkylthio, Ci_6-alkoxy, Ci_6-alkyl, halo-C^ό-alkyl; and heteroaryl optionally substituted by one or more of halogen.
2. The compound according to claim 1 wherein Ar is phenyl, wherein the phenyl may be substituted by one or more of Ci_6-alkoxy.
3. The compound according to any one of claims 1 to 2 wherein the phenyl may be substituted by one or more of methoxy.
4. The compound according to any one of claims 1 to 3 wherein Ar is 3,4- dimethoxyphenyl.
5. The compound according to any one of claims 1 to 4 wherein R1 is methyl.
6. The compound according to any one of claims 1 to 5 wherein R3 is selected from phenyl optionally substituted by one or more of bromo, chloro, cyano, (difluoromethyl)thio, fluoro, iodo, methoxy, methyl, trifluoromethyl, (trifluoromethyl)thio; l,3-benzodioxol-5-yl optionally substituted by one or more of fluoro; and pyridyl.
7. The compound according to any one of claims 1 to 6 wherein R3 is selected from A- bromo-3-methylphenyl, 3-bromophenyl, 4-bromophenyl, 4-bromo-2- (trifluoromethyl)phenyl, 3-chloro-2-fluorophenyl, 3-chloro-4-fluorophenyl, 3- chlorophenyl, 4-chlorophenyl, 4-chloro-3-(trifluoromethyl)phenyl, 3-cyanophenyl, A- cyanophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 3,4-dichlorophenyl, 2,2-difluoro- l,3-benzodioxol-5-yl, 3-(difluoromethyl)thiophenyl, 2,5-difluorophenyl, 3,4- difluorophenyl, 3,5-difluorophenyl, 3,4-dimethoxyphenyl, 3,5-dimethylphenyl, 3- fluorophenyl, 4-fluorophenyl, 2-fluoro-3-(trifluoromethyl)phenyl, 2-fluoro-4- (trifluoromethyl)phenyl, 3-fluoro-4-(trifluoromethyl)phenyl, 3-fluoro-5-
(trifluoromethyl)phenyl, 4-fluoro-3-(trifluoromethyl)phenyl, 4-iodophenyl, 2,3,4- trifluorophenyl, 3,4,5-trifluorophenyl, 3-(trifluoromethyl)phenyl, A- (trifluoromethyl)phenyl, 4-(trifluoromethyl)thiophenyl, and 4-pyridyl.
8. The compound according to any one of claims 1 to 7, which is a compound selected from the group consisting of:
N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-yl]-4- iodobenzamide;
N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-yl]-3,4- dimethoxybenzamide trifluoroacetate;
4-chloro-N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-
5-yl]benzamide;
N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-yl]-4- fluorobenzamide ; 4-bromo-N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-
5-yl]benzamide;
N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-yl]-3- fluoro-4-(trifluoromethyl)benzamide;
4-bromo-N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol- 5-yl]-3-methylbenzamide;
N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-yl]-4- fluoro-3-(trifluoromethyl)benzamide;
N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-yl]-4-
(trifluoromethyl)benzamide ; N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-yl]-2,2- difluoro-l,3-benzodioxole-5-carboxamide;
N-(3-chloro-4-fluorophenyl)-N'-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2- methyloctahydro-lH-isoindol-5-yl]urea trifluoroacetate; N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-
2-methyloctahydro- lH-isoindol-5-yl]urea trifluoroacetate;
N-(3,5-difluorophenyl)-N'-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2- methyloctahydro-lH-isoindol-5-yl]urea trifluoroacetate;
N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-yl]-N'- (2,3,4-trifluorophenyl)urea trifluoroacetate;
N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-yl]-N'-
(3-fluorophenyl)urea trifluoroacetate;
N-(3-chlorophenyl)-N'-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro- lH-isoindol-5-yl]urea trifluoroacetate; N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5- yl]isonicotinamide 1-oxide trifluoroacetate;
N-(3,4-difluorophenyl)-N'-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2- methyloctahydro-lH-isoindol-5-yl]urea;
N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-yl]-N'- [3-fluoro-5-(trifluoromethyl)phenyl]urea acetate;
N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-yl]-N'-
[2-fluoro- 3 - (trifluoromethyl)phenyl] urea acetate ;
N-(2,5-difluorophenyl)-N'-[(3aS,5R,7aR)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro- lH-isoindol-5-yl]urea; 3,4-dichloro-N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH- isoindol-5-yl]benzamide;
N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-yl]-N'-
(3,4,5-trifluorophenyl)urea;
N-[(3aS*,5S*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-yl]-N'- [2-fluoro-3-(trifluoromethyl)phenyl]urea acetate;
3,4-dichloro-N-[(3aS*,5S*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH- isoindol-5-yl]benzamide;
N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-yl]-N'-
[4-fluoro-3-(trifluoromethyl)phenyl]urea trifluoroacetate; N-[(3aS,5R,7aR)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-yl]-N'-[4- fluoro-3-(trifluoromethyl)phenyl]urea;
N-[(3aR,5S,7S)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-yl]-N'-[4- fluoro-3-(trifluoromethyl)phenyl]urea; N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-yl]-3- fluorobenzamide trifluoroacetate;
3-chloro-N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-
5-yl]benzamide trifluoroacetate;
3-bromo-N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol- 5-yl]benzamide trifluoroacetate;
3-[(difluoromethyl)thio]-N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2- methyloctahydro-lH-isoindol-5-yl]benzamide trifluoroacetate;
3-Cyano-N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-
5-yl]benzamide trifluoroacetate; 4-Cyano-N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-
5-yl]benzamide trifluoroacetate;
N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-yl]-3,4- difluorobenzamide trifluoroacetate;
N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-yl]-3- fluoro-5-(trifluoromethyl)benzamide trifluoroacetate;
N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-yl]-2- fluoro-4-(trifluoromethyl)benzamide trifluoroacetate;
N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-yl]-4-
[(trifluoromethyl)thio]benzamide trifluoroacetate; 3-chloro-N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-
5-yl] -2-fluorobenzamide trifluoroacetate;
N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-yl]-2,5- difluorobenzamide trifluoroacetate;
N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-yl]-N'- (3,5-dimethylphenyl)urea trifluoroacetate;
N-(2,5-dichlorophenyl)-N'-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2- methyloctahydro-lH-isoindol-5-yl]urea trifluoroacetate;
N-(2,4-dichlorophenyl)-N'-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2- methyloctahydro-lH-isoindol-5-yl]urea trifluoroacetate; N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-yl]-N'- (4-iodophenyl)urea trifluoroacetate;
N-[(3aS,5R,7aR)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-yl]-3- fluoro-4-(trifluoromethyl)benzamide trifluoroacetate; N-[(3aR,5S,7aS)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-yl]-3- fluoro-4-(trifluoromethyl)benzamide trifluoroacetate;
N-[4-bromo-2-(trifluoromethyl)phenyl]-N'-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)- 2-methyloctahydro- lH-isoindol-5-yl]urea trifluoroacetate;
N-(3-cyanophenyl)-N'-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro- lH-isoindol-5-yl]urea trifluoroacetate; and
N-[(3aS*,5R*,7aR*)-7a-(3,4-dimethoxyphenyl)-2-methyloctahydro-lH-isoindol-5-yl]-3- (trifluoromethyl)benzamide trifluoroacetate.
9. A process for the preparation of a compound according to anyone of claims 1 to 8 comprising either of the following steps:
(a) acylation of an amine with a substituted benzoyl chloride,
(b) treatment of an amine with 4-carboxypyridine-N-oxide in the presence of a coupling agent,
(c) treatment of an amine with a substituted aryl isocyanate, (d) treatment of an amine with triphosgene and another amine.
10. A compound according to any one of claims 1 to 8 for use in therapy.
11. A compound according to any one of claims 1 to 8 for medical use in the treatment or prophylaxis of obesity, diabetes mellitus, hyperlipidemia, hyperglycemia, depression, anxiety, and urinary incontinence, and for modulation of appetite.
12. A compound according to any one of claims 1 to 8 for medical use in the treatment or prophylaxis of disorders relating to the MCHlR receptor and for modulation of appetite.
13. A compound according to claim 12, wherein the disorders are selected from obesity, diabetes mellitus, hyperlipidemia, hyperglycemia, depression, anxiety, and urinary incontinence.
14. A compound according to any one of claims 1 to 8 for use in conjunction with other compounds active towards other receptors, such as MC-4 agonists, 5HT2c agonists, or 5HT6 antagonists.
15. A compound according to any one of claims 1 to 8 for use in conjunction with anti- obesity medicaments.
16. A pharmaceutical formulation containing a compound according to any one of claims 1 to 8 as an active ingredient, in combination with a pharmaceutically acceptable diluent or carrier.
17. A pharmaceutical formulation for use in the treatment or prophylaxis of obesity wherein the active ingredient is a compound according to any one of claims 1 to 8.
18. A method for the treatment or prophylaxis of obesity, diabetes mellitus, hyperlipidemia, hyperglycemia, depression, anxiety, urinary incontinence, and for modulation of appetite, said method comprising administering to a subject in need of such treatment an effective amount of a compound according to any one of claims 1 to 8.
19. A method for the treatment or prophylaxis of disorders related to the MCHlR receptor and for modulation of appetite, said method comprising administering to a subject in need of such treatment an effective amount of a compound according to any one of claims 1 to 8.
20. A method according to claim 19, wherein the disorders are selected from obesity, diabetes mellitus, hyperlipidemia, hyperglycemia, depression, anxiety, and urinary incontinence.
21. A method for modulating MCHlR receptor activity, comprising administering to a subject in need thereof an effective amount of a compound according to any one of claims l to 8.
22. Use of a compound according to any one of claims 1 to 8 in the manufacture of a medicament for use in the treatment or prophylaxis of obesity, diabetes mellitus, hyperlipidemia, hyperglycemia, depression, anxiety, and urinary incontinence, and for modulation of appetite.
23. Use of a compound according to any one of claims 1 to 8 in the manufacture of a medicament for use in the treatment or prophylaxis of disorders related to the MCHlR receptor and for modulation of appetite.
24. Use according to claim 23, wherein the disorders are selected from obesity, diabetes mellitus, hyperlipidemia, hyperglycemia, depression, anxiety, and urinary incontinence.
25. Use of a compound according to any one of claims 1 to 8 in the manufacture of a medicament for use in conjunction with other compounds active towards other receptors, such as MC-4 agonists, 5HT2c agonists, or 5HT6 antagonists.
26. Use of a compound according to any one of claims 1 to 8 in the manufacture of a medicament for use in conjunction with anti-obesity medicaments.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0500918-8 | 2005-04-25 | ||
SE0500918 | 2005-04-25 | ||
US67714905P | 2005-05-03 | 2005-05-03 | |
US60/677,149 | 2005-05-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006114402A1 true WO2006114402A1 (en) | 2006-11-02 |
Family
ID=46045531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2006/061782 WO2006114402A1 (en) | 2005-04-25 | 2006-04-24 | Substituted octahydroisoindoles as antagonists of melanin concentrating hormone receptor 1 (mch1r) |
Country Status (2)
Country | Link |
---|---|
US (1) | US20070149600A1 (en) |
WO (1) | WO2006114402A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015172059A (en) * | 2008-12-16 | 2015-10-01 | スノビオン プハルマセウトイカルス インコーポレイテッド | Triple reuptake inhibitors and methods of their use |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6288104B1 (en) * | 1996-06-04 | 2001-09-11 | African Natural Health Cc | Pharmaceutical compositions containing mesembrine and related compounds |
WO2002057233A1 (en) * | 2000-12-01 | 2002-07-25 | Schering Corporation | Mch antagonists and their use in the treatment of obesity |
WO2003087045A1 (en) * | 2002-04-09 | 2003-10-23 | 7Tm Pharma A/S | Novel methoxybenzamide compounds for use in mch receptor related disorders |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6228104B1 (en) * | 1999-06-18 | 2001-05-08 | Novare Surgical Systems, Inc. | Surgical clamp having replaceable pad |
WO2005051381A1 (en) * | 2003-11-26 | 2005-06-09 | Biovitrum Ab | Substituted urea-octatydroindols as antagonists of melanin concentrating hormone receptor 1 (MCH1R) |
-
2006
- 2006-04-24 WO PCT/EP2006/061782 patent/WO2006114402A1/en active Application Filing
- 2006-04-24 US US11/409,704 patent/US20070149600A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6288104B1 (en) * | 1996-06-04 | 2001-09-11 | African Natural Health Cc | Pharmaceutical compositions containing mesembrine and related compounds |
WO2002057233A1 (en) * | 2000-12-01 | 2002-07-25 | Schering Corporation | Mch antagonists and their use in the treatment of obesity |
WO2003087045A1 (en) * | 2002-04-09 | 2003-10-23 | 7Tm Pharma A/S | Novel methoxybenzamide compounds for use in mch receptor related disorders |
Non-Patent Citations (2)
Title |
---|
BROWNING A: "Recent developments in the discovery of melanin-concentrating hormone antagonists: Novel antiobesity agents", EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 14, no. 3, 2004, pages 313 - 325, XP002365091, ISSN: 1354-3776 * |
COLLINS C A ET AL: "PROSPECTS FOR OBESITY TREATMENT: MCH RECEPTOR ANTAGONISTS", CURRENT OPINION IN INVESTIGATIONAL DRUGS, PHARMAPRESS, US, vol. 4, no. 4, 1 April 2003 (2003-04-01), pages 386 - 394, XP009060720, ISSN: 1472-4472 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015172059A (en) * | 2008-12-16 | 2015-10-01 | スノビオン プハルマセウトイカルス インコーポレイテッド | Triple reuptake inhibitors and methods of their use |
JP2018009003A (en) * | 2008-12-16 | 2018-01-18 | サノビオン ファーマシューティカルズ インクSunovion Pharmaceuticals Inc. | Triple reuptake inhibitors and methods for using them |
Also Published As
Publication number | Publication date |
---|---|
US20070149600A1 (en) | 2007-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2006325815B2 (en) | Azepinoindole derivatives as pharmaceutical agents | |
US9133122B2 (en) | Amide compounds, compositions and uses thereof | |
JP4550072B2 (en) | Chemokine receptor antagonist | |
CA2780218C (en) | Morpholinothiazoles as alpha 7 positive allosteric modulators | |
KR101804588B1 (en) | Hematopoietic growth factor mimetic small molecule compounds and their uses | |
EP3325490B1 (en) | 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists | |
RU2449990C2 (en) | Indoles as 5-ht6 modulators | |
RU2408594C2 (en) | Antagonists of thrombin receptor | |
JP2010508288A (en) | Heterocyclic amide compounds useful as kinase inhibitors | |
CA2598133A1 (en) | Pgd2 receptor antagonists for the treatment of inflammatory diseases | |
KR20110031318A (en) | 2,4'-bipyridinyl compounds as protein kinase d inhibitors useful for the treatment of ia heart failure and cancer | |
JP2002542245A (en) | Substituted imidazoles, their manufacture and use | |
EP2016058A1 (en) | Inhibitors of c-fms kinase | |
US20100234419A1 (en) | Substituted 3-aminoisoxazolopyridines as kcnq2/3 modulators | |
KR20060021373A (en) | New azetidine compounds | |
CA2524019A1 (en) | Positive modulators of nicotinic acetylcholine receptors | |
US20050239841A1 (en) | New compounds | |
JP2002529463A (en) | Compound | |
KR20100135248A (en) | Indolinone compound | |
WO2001070703A2 (en) | Substituted 1-(4-aminophenyl)imidazoles and their use as anti-inflammatory agents | |
US20050192339A1 (en) | Compounds | |
US20070149600A1 (en) | Substituted octahydroisoindoles | |
EP1765814A1 (en) | Condensed thiophene derivatives and their use as cyclic glp-1 agonists | |
WO2006036031A1 (en) | Fused furan derivative and use thereof | |
CN109748923A (en) | Containing benzo [4,5] imidazoles [1,2-a] pyrazinones derivative and preparation method thereof and purposes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: RU |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06754809 Country of ref document: EP Kind code of ref document: A1 |